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ABSTRACT
IDENTIFICATION AND CHARACTERIZATION OF GENES ASSOCIATED
WITH V-JUN INDUCED CELL TRANSFORMATION
Martin Hadman
Eastern Virginia Medical School, 1995
Advisor: Dr. Timothy J. Bos
The u-jun oncogene was initially identified as the causative agent for
fibrosarcomas in chickens. Studies show that overexpression of v-Jun proteins
transforms chicken embryo fibroblasts (CEF) in vitro, and forms tumors in
chickens in vivo. The mechanisms for this are not clearly defined. Conceivably,
overexpression of an unregulated transcription factor w ould cause cell
transformation by illicit regulation of its target genes. In support of this, we
show that in vivo v-Jun complexes exhibit differential binding to in vitro
generated AP-1 and 'AP-l like' target sequences, suggesting that the pattern of
target gene expression is altered during cell transformation. With this in mind,
we set out to identify genes associated with v-Jun induced cell transformation.
We have isolated several clones by subtractive hybridization, and a modified
differential display procedure. One of these is clone 4, showing strong sequence
homology, both at nucleotide and amino acid level, to cysteine thiol proteases.
Northern blot analysis shows that the steady state levels of clone 4 mRNA are 3
to 7 times higher in v-Jun transformed CEF (VJ-1), when compared to c-Jun
overexpressing CEF (CJ-3), or normal CEF infected with vector sequences only
(RCAS).
Another is clone 15-15, showing strong sequence identity to the chicken
Apolipoprotein A1 (ApoAl) gene. Northern blot analysis demonstrates that the
steady state levels of ApoAl mRNA in RCAS is 3 to 10 times higher than in VJ-1
cells, indicating that v-Jun m ight repress this gene by transcriptional
mechanisms. To investigate this possibility, we generated several ApoAl
reporter CAT constructs containing 5' deletions in the promotor, and tested
them in VJ-1 and RCAS cells. Our findings suggest that three potential cis-acting
sequences could regulate this promotor in normal RCAS CEF. Quite remarkably,
none of these constructs were transcriptionally active in VJ-1 cells. DNA binding
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studies utilizing one of the potential cis-acting regions, suggests that a specific
factor is present in normal nuclear extracts, but absent from v-Jun transformed
extracts. This observation suggests that this specific factor may be a positive
activator protein. In addition, actinomycin D studies demonstrate that the
ApoAl mRNA has a long half-life of up to 20 hours. We therefore propose that
A poA l is positively regulated by at least three cis-acting sequences, and
m aintained at high steady state levels in norm al CEF. Several possible
mechanisms exist to explain ApoAl repression in normal RCAS and VJ-1 cells.
One possibility is the direct repressor mechanism, whereby a silencer region
directly inhibits ApoAl expression in normal cells. In VJ-1 cells however, a
squelching mechanism could predominate. In this case, overexpressed v-Jun
proteins would sequester and inactivate potential factors that positively regulate
ApoAl transcription, leading to repression.
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Chapter I. INTRODUCTION

Discovery of the v-ju n oncogene.
Avian sarcoma virus (ASV-17) was isolated from a spontaneous sarcoma
in adult chickens. Retroviral isolates of ASV-17 form polyclonal tumors when
injected into chickens, in vivo, and transform chicken embryo fibroblasts cultures
(CEF), in vitro. These transformed fibroblasts have a characteristic fusiform
shape organized in parallel arrays when grown in liquid medium, and form
anchorage independent colonies in soft agar. Interestingly, in vitro transformed
CEF are not immortalized by ASV-17; instead they become highly vacuolated
after 25 to 30 cell doublings, and die. In contrast, cultures derived from ASV-17
induced tumors have a longer lifespan,

indicating that additional genetic

modifications are responsible for cell immortalization (reviewed in ref 35).

Further studies show that ASV-17 is a defective retrovirus requiring non
defective helper virus to replicate efficiently, and produce infectious progeny.
Characterization of the ASV-17 retroviral genome revealed a 0.93 kb insert
showing strong homology to a cellular c-jun gene, and to the DNA binding
domain of a yeast transcription factor, GCN4. When either the cellular gene (cjun) or the ASV-17 derived insert (v-jun) was cloned into a retroviral expression

vector, RCAS, and overexpressed in CEF,

phenotypic properties similar to

ASV-17 induced cell transformation occurred in vitro. This finding demonstrates
that the factor responsible for transformation was acquired from the cell by
ASV-17, and establishes that the jun gene is a true oncogene (35).
p ag el
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Discovery of c-jun.
Seminal studies propelling jun into forefront of oncogene research began
with the characterization of a transcription factor complex from HeLa cell
extracts that specifically recognized the SV40 enhancer element and the human
metallothionein HA (hMIIA) promotor. This transcription factor complex, called
AP-1 fraction, (activator protein-1) binds the sequence, TGA(C/G)TCA. This
sequence, later called the AP-1 DNA binding site, is present in regulatory
regions of several viral and cellular genes. Interestingly, this site is homologous
to the TRE site (TPA responsive element) responsible in the regulation of cellular
genes stimulated by cell treatment with phorbol esters. Definitive proof that Jun
protein is a component of the AP-1 fraction comes from immunoblot assays
showing that antibodies to v-Jun peptides, PEP1 and PEP2, recognize a 39 kd
polypeptide in purified AP-1 preparations. Sequencing of AP-1 tryptic digests
showed strong similarity to predicted Jun amino a d d sequences. Moreover,
bacterial expressed Jun proteins are able to bind the AP-1 site. Further studies
showed that the AP-1 fraction consists of other proteins involved in recognizing
the AP-1 binding site: these indude the well characterized oncogene, c-Fos,
other Fos related proteins, and Jun related proteins. Further characterization of
Jun and Fos proteins demonstrated that they form homodimers and function as
important cellular transcription factors. These observations provided incentive
to investigate the role of Jun and other AP-1 factors in gene regulation and
cellular function (35).

Role of c-Jun in cellular events.
The c-jun gene is expressed at basal levels in most tissues, and is rapidly
induced in response to serum and extracellular growth fadors (29, 35). For this
reason,

c-Jun activity has been implicated in several growth related events
page 2
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including:

cell growth and proliferation (66),

differentiation (14, 93-96),

embryonic development (65), wound healing (35), tissue regeneration (35), and
UV induced cell damage (68). Interestingly, a recent study demonstrates a role
for Rb (Retinoblastoma susceptibility gene product) in c-Jun regulation, and
further suggests that these transcription factors could regulate cell growth (98).
It is therefore possible that Rb/Jun targets might include cell cycle regulators.
Indeed,

the expression of c-jun as an immediate early gene (29, 35, 66, 67)

correlates well with induction of cell growth, implying that it could potentially
effect downstream targets to regulate the entrance or exit from the cell cycle.

c-Jun structure.
The c-jun gene is highly conserved in several species, and present in non
vertebrates like Drosophila, and in vertebrate species of chickens, mouse, rat,
and humans. The human c-jun gene, located on chromosome lp3.1-3.2, is a
single copy gene, as determined by stringent Southern blot analysis of genomic
restriction fragments with a jun probe. Interestingly, the 984 bp coding region
does not contain any introns. Other important characteristics include a long GC
rich 5' untranslated region, and an AT rich 3' region, common in growth factor
genes and proto-oncogenes. The promotor region contains several transcription
factor binding sites, including an AP-1, SP-1 and CTF sites, and two variant
TATA-like boxes. Two major transcripts, 2.7 and 3.4 kb, are produced from
multiple transcription initiation sites and two poly A addition signals. Although
several ATG start sites exist, further studies suggests that the various c-jun
transcripts all code for the same Jun protein (29,35).

The c-jun gene codes for a 39 kd protein. Functional domains include the
transcriptional activation region, the basic region, and leucine zipper, (figure 1).
page 3
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Figure 1. Structural differences between c-Jun and v-Jun.
The figure above shows the functional domains on the c-Jun protein. Note
that v-Jun contains several structural alterations, including a gag region
acquired from the transforming retrovirus, a 27 amino acid deletion in the
transactivation domain (called the delta region), and three point mutations
at the COOH region. The numbers above denote positions o f amino acid
residues; G: glycine; S: serine; C: cysteine; R: arginine; F: phenylalanine.

page 4
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The COOH terminal half of the Jun protein contains the basic region and leucine
zipper motif, responsible for dimerization and subsequent DNA binding to the
AP-1 site. The leucine zipper consists of five leucine residues which are equally
spaced by seven amino ad d residues. Structural analysis suggests that this
arrangement forms an alpha helical structure with the leucine residues
protruding from the sides and aligning in a straight line,

favorable for

dimerization with other proteins with similar conserved structures.

These

proteins indude the yeast activator protein, GCN4, the fos family of proteins, cFos, Fra-2, andFosB, and Jun family of proteins, JunBandJunD. Dimerization
with c-Jun is spedfic since other proteins containing leucine zipper motifs, like cMyc, do not form heterodimers with either Jun or Fos proteins. Moreover,
CREBII, which belongs to the CREB (cAMP responsive element binding) family
of proteins, can form heterodimers with c-Jun but not c-Fos. This observation
suggests that dimerization specifidty is maintained by the structural organization
of the leucine zipper conserved among Jun, Fos and CREB family of proteins.
Other regulatory regions outside the conserved leucine zipper domain might
regulate dimerization, since neither c-Fos nor Fra-1 form homodimers; other
CREB members form homo- and heterodimers among their family members,
but not with c-Jun proteins (29,35).

Immediately upstream from the leudne zipper region is the basic domain,
or DNA binding domain. This region, also conserved in Jun, Fos, and CREB,
families,

consists of long stretches of positively charged amino acids.

Site

directed mutagenesis suggest that the basic region is responsible for DNA
binding and not dimerization, although other domains outside the Jun basic
domain could contribute to the DNA binding affinity or specifidty to target
sequences.

This observation was verified by several domain swapping
page 5
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experiments. Since dimerization precedes DNA binding,

it is possible that

dimerization induces conformational changes favorable to DNA binding
specificity (29,35). These observations imply that dimerization partners, or their
availability, influence DNA binding and the overall regulation of target gene
expression.

The transcriptional activation domain (TAD) of c-Jun, located in the amino
terminal half, consists of negatively charged amino adds, induding proline and
glutamine. This region of addic amino adds, conserved in the Jun family of
proteins, can confer an activator protein of new sequence specifidty when fused
to a heterologous DNA binding domain. A duster of proteins with a molecular
mass around 52 to 55 kDa (p52/55) specifically recognize the Jun TAD, and could
potentially regulate the transcriptional activation of Jun target genes (64).

More importantly, v-Jun has a 27 amino ad d deletion, called the delta
region, that maps to the transactivation domain of c-Jun. While this deletion
does not appear to affect the overall transactivation potential of v-jun, it reduces
its dimerization and DNA binding properties (29). Moreover, the delta region
could regulate significant post-translational modifications of c-jun,

since a

peptide encoding this region reduces the ability of JNK (Jun N-terminal kinase)
to effidently phosphorylate the Jun protein in vitro (102). Evidence suggests that
kinase phosphorylation at ser 63/73 affects the dimerization and DNA binding
properties of Jun proteins (58). The relevance of these observations to c-Jun
regulation and cell transformation will be discussed later.

Regulation of c-Jun activity.
c-Jun activity is stringently regulated during the normal cell process, as
page 6
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aberrant Jun activity leads to cell transformation in vitro, and tumorigenesis in
vivo. Cellular mechanisms regulating c-Jun can be divided into: (a) factors that

enhance its expression at the transcriptional and translational level, including the
factors that regulate its mRNA and protein stability; (b) signal transduction
mechanisms that effect post-translational modifications, which in turn regulate
its overall function including dimerization and transactivation; and, (c) other
poorly defined regulatory mechanisms, including the role of potential stabilizing
factors, and control of transport to the nucleus (75 -78).

Signal transduction events regulating c-Jun.
Binding of extracellular factors to cell surface receptors initiates multiple
signal transduction cascades. Studies indicate that some of these signaling events
regulate Jun related responses by activating basal levels of preexisting c-Jun
proteins present in resting Go cells (6,39). These activated Jun proteins form Jun
heterodimers,

and positively autoregulate c-jun gene transcription,

and

coordinate the expression of Jun target genes necessary to effect cellular
responses. Northern blot analyses indicate a 30 fold increase in steady state
levels of c-jun mRNA

30 minutes after serum treatment,

accompanied by

increased Jun heterodimers formation, and binding to AP-1 sites. Expression of
corresponding target genes, such as collagenase, occurs 8 to 12 hours later,
depending on the cell type. In this way, amplification of an initial transient
extracellular signal to achieve the desired cellular response, is mediated by
activated Jim heterodimers (29,35).

Several extracellular factors and stimuli inducing c-jun gene expression, cJun activation, as well as Jun target gene expression, are shown in table 1. Some
factors, such as TNF-alpha, andTGF-beta, induce prolonged c-jun transcription
page 7
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Table 1. Listing of factors known to affect c-jun gene expression.
stim u li________ comments_________________________________ reference
serum

transient increase of c-jun mRNA in most cells,
including fibroblasts and mouse 3T3 cells

NGF

decreased c-jun transcription in PC-12 cells;
response is differentiation dependent

90, 91

EGF

stimulation of c-jun mRNA in N IH /3T3, rat
fibroblasts

79,

TGF-B

stimulation of c-jun mRNA in adult rat
hepatocytes and A 549 human lung
adenocarcinoma;

80, 85

TNF

prolonged activation of c-jun mRNA in human fetal
fibroblasts, monocytes and granulocytes;

81, 82

IL-1 and IL-2

enhanced c-jun mRNA expression in T-cells;

86-

IL-3

no c-jun mRNA detected in 32D hemato poetic
cells but increases noted in FDCP-1 cells;

66 ..

IL -6 ,
oncostatin M

rapid and transient c-jun mRNA increase in human
fibroblasts;

83-

endothelin
isopeptides

induction of c-jun mRNA and activity in mesangial
cells;

84-

GM-CSF

c-jun expression and AP-1 enhancer activity
observed in U-937 cells;

72-

ju n /fo s

positive auto-regulation in HeLa, HEPG2, F9

29,

CREB

phosphorylated CREB activates c-jun gene
transcription in NIH 3T3;

88-

retinoic acid

strong c-jun mRNA expression in undifferentiated
EC stem cells

89-

NF-jun

transcription factor affects c-jun transcription in
human myeloid leukemia cells

87-

Rb

Rb activates c-jun transcription thru the SP-1
binding site

98-

progesterone

down regulation of c-Jun in avian oviduct

108..

FSH/ follicle
stimulating
hormone

FSH inhibits c-jun in Rat Steroli cells

99-

29, 35

59

35

page 8
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rates,

and higher steady state levels of c-jun message.

Further evidence

suggests that the cell type involved, the duration of cell treatment, and the
convergence of dual signals are responsible, as will be discussed later. The first
signal pathway identified to induce c-jun transcription and activity is the protein
kinase C (PKC) pathway, as cell treatment with phorbol ester, such as TPA,
both increase c-jun mRNA steady state levels and c-Jun activity, as evidenced by
binding to TPA responsive elements (TEE/ AP-1 sites) (29,35).

A listing of kinases and phosphatases known to regulate c-Jun activity are
shown in table 2. Extensive studies show that c-Jun activity is regulated by posttranslational modifications involving phosphorylation and dephosphorylation at
several potential serine and threonine sites on the c-Jun protein. In resting cells,
latent or inactive c-Jun is phosphoiylated at the C-terminal ser 243 residue,
located just upstream from the DNA binding site. PKC activation induces a rapid
dephosphoiylation at this site, associated with increased binding to AP-1 sites
(56). Studies also show that resting cells have a dephosphorylated ser 63/ 73
residue at the N-terminal half of c-Jun, thereby restricting its activity. MAP
kinases (Mitogen Activated Protein-serine Kinases) induced by mitogens,
phorbol esters, and an activated ras oncogene, specifically phosphorylate these
sites,

resulting in an increase in c-Jun transactivation activity (7, 73). This

suggests that

a balanced phosphorylation/ dephosphorylation mechanism

regulates c-Jun activity. However, these observations contrast with another
study demonstrating that phosphorylation of Jun at either ser 63 / 73, or ser-246,
does not significantly alter c-Jun dimerization,

DNA binding,

or in vitro

transactivation, and strongly suggest that these sites may not be critical for c-Jun
regulation (57).

Although the discrepancy may be in the use of different cell

types and extracellular stimuli utilized in each study, it is clear that the regulation
page 9
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enzyme_

phosphorylation site affected

comments

reference

PKC / TPA

c-Jun is not a direct substrate; purified
c-Jun is not phosphorylated in vitro;
phosphorylation and dephosphorylation
o f potential ser and th r sites noted in
HeLa and fibroblasts cells;

cell treatm ent with TPA increases ju n /fos
heterodimerization and binding to A P -1 /
TRE sites

2 9 , 3 5 , 56

casein kinase II

phosphorylation a t thr-231 and
s e r-2 4 9

phosphorylation negatively affects DNA
binding and AP-1 activity

9 7 ..

GSK-3; glycogen
synthetase kinase-3

phosphorylation a t th r-2 3 9 , ser-243,
ser-249; in vitro

decrease in DNA binding, in vitro;

5 6 ..

Ha-Ras / MAP kinase
and c d c /p 3 4 kinase

phosphorylation a t ser 6 3 /7 3 ;
dephosphorylation at th r-2 3 9 ,
s e r-2 43 , ser-249

phosphorylation/ dephosphorylation
mechanisms activate c-Jun;

7, 5 7, 73

protein phosphatase 2A
(P P 2A )

sites not determined; variations in
phosphorylation demonstrated by
changes in electrophoretic mobility;

loss of PP2A activity is associated with
deletion in the delta region;

7 0 , 71

JNK/ SAPK kinase activity is regulated by
delta region;

5 8 , 9 2 , 101,

JNK / SAPK (Jun N
terminal kinase/ Stress
activated protein
kinase)

phosphorylation at ser 6 3 / 7 3 ,
vitro and in vivo;

both in

102,

of c-Jun activity is complex, requiring other post-translational regulatory events,
and stabilizing factors. Indeed, other post-translational modifications include
glycosylation (35), and a reduction/ oxidation pathway, as will be discussed
later.

Intensive research committed to elucidating the active participants
involved in extracellular signaling have established that MAP kinases are
important in growth factor responses and c-Jun protein activation.

(39, 74).

Studies report a UV induced signaling pathway involving Ras, Raf and MAP
kinases in the regulation of c-Jun activity. The terminal effector in the cascade
directly responsible for c-Jun phosphorylation at ser-63/ 73 residues belongs to a
family of related MAP kinases (7, 8), known as the JNK-1 kinase (jun -Nterminal kinase) (58), or Stress Activated Protein Kinase (SAPK) (101). In vitro
studies demonstrate a direct binding between a purified JNK to c-Jun,
implicate the importance of delta domain.

and

In vivo studies confirm that c-Jun

phosphorylation enhances DNA binding and transactivation of AP-1 sites. The
UV induced pathway mentioned above is related to a growth factor signaling
pathway, in that both pathways utilize Ras, Raf, and MAP kinases (68). They
differ in that the latter pathway involves extracellular-signal-regulated-kinases
(ERKs) (74). These pathways are distinct since agents that activate the former,
such as UV and stress,
Moreover,

only weakly activate the ERK pathway (39, 74).

studies show that the existence of a Ras signaling pathway that

activates c-Jun, but does not involve ERKs (103). Although extracellular growth
factors or receptor tyrosine kinases have been established in the regulation of cJun activity, the immediate effectors acting on c-Jun have yet to been identified.
For instance,

the phosphatase(s) directly involved in activating c-Jun by

dephosphorylation at ser 246, or at other potential C-terminal sites, have yet to
page 11
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be determined. It is conceivable that this putative phosphatase is regulated by
the ERKs, since PKC, an important constituent of the tyrosine kinase pathway,
induces dephosphorylation at this site (56).

Extensive studies demonstrate that other signal pathways may be
involved in c-Jun regulation. For instance, a PKC-independent pathway induced
by the EGF receptor has been proposed to activate c-jun transcription (59). In
this study, EGF or serum stimulation was able to induce c-jun gene transcription
in PKC depleted NIH /3T3 cells. Another study investigated the role of diacylglycerol and Ca2+ in the regulation of c-Jun activity in U-937 cells (60). When
cells are treated w ith either low doses of diacyl-glycerol, or agents increasing
intracellular Ca2+, c-jun gene transcription was observed without changes in cJun activation or AP-1 enhancer activity. However, when these agents act in
synergy, AP-1 enhancer activity and expression of U-937 differentiation markers
were noted.

This last study emphasizes that regulation of c-jun gene

transcription and AP-1 enhancer activity could be under separate control. It also
suggests that dual converging pathways serve to regulate c-Jun activity. In
support of this,

studies demonstrate that activation of JNK-1 in T-cells,

is

dependent on Ca +2 mobilization and PKC activation (92).

Another interesting study reports that a factor isolated and characterized
from HeLa cell extracts, the Ref-1 gene product, facilitates AP-1 DNA binding
activity. (61, 62). Reduction of a conserved cys-272 residue on c-Jun protein,
with either DTT, thioredoxin, or a purified Ref-1 gene product, increased DNA
binding of Jim /Fos heterodimers to AP-1 sequences,

in vitro.

In contrast,

chemical oxidation or modification of critical residues from cysteine to serine,
inhibits DNA binding.

Interestingly,

the Ref-1 gene product has apurinic/

page 12
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apyrimidinic (AP) endonuclease activity involved in DNA repair. The redox and
DNA repair properties of Ref-1 can be distinguished biochemically. The reports
further suggest that a redox signaling pathway could regulate c-Jun activity
during periods of oxidative stress, or severe DNA damage. In support of this, a
redox signaling pathway involving nitric oxide (NO) proposes that transcription
factors involving CREB, NF-KB, c-Jun and c-Fos are likely NO targets (69). It
remains to be shown how these events relate to or differ from the UV and stress
induced signaling events known to regulate c-Jun.

Dimerization regulates c-Jun activity.
Another important aspect in the regulation of c-Jun activity is
dimerization. Since this critical event is a prerequisite for DNA binding, it
follows that factors regulating dimerization could ultimately regulate c-Jun
activity. As described earlier, c-Jun specifically interacts with other protein
family members that have an identical or conserved leucine zipper structure.
Since other leucine zipper containing proteins do not interact with c-Jun, an
important aspect in maintaining dimerization specificity is the structure of the
leucine zipper itself.

But how does dimerization regulate c-Jun activity? While c-Jun can form
homodimers, it binds weakly to AP-1 sites, in vitro, as compared with Jun/Fos
heterodimers,

suggesting that Jun dimer partners influence the binding

specificity and affinity to AP-1 sites. Indeed, studies show that the composition
of Jun homodimers and heterodimers change rapidly during cell stimulation (29).
During resting Go states, c-Jun homodimers predominate. Immediately after
stimulation, the composition changes to c-Jun/c-Fos heterodimers, followed by
c-Jun homodimers after c-Fos levels decay. Heterodimerization with JunD and
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

JunB also occurs, but play a minor role. Further studies suggest that while Jun
homodimers are responsible for maintenance of basal cellular function,

Jun

heterodimers play a role in initiating the induction response. More importantly,
it demonstrates that the availability of Jun dim er partners at any given time
point could determine Jun target specifidty, and consequent regulation of Jun
target genes. Interestingly, c-Jun can interact with other transcription factors
that do not involve the leucine zipper. These indude the steroid family of
transcription factors, myoD, NF-KB, and NF/AT complex. This observation
further supports the assumption that the promiscuous behavior of c-Jun endows
it with new DNA binding specifidty, which could be responsible for various
cellular responses.

Negative regulation of c-Jun activity.
An important requirement in the maintenance of appropriate cellular
function is the immediate inactivation of c-Jun activity after extracellular
stimulation. Negative regulation can be achieved, in part, by decreasing c-Jun
protein levels. One mechanism is the transcriptional attenuation of c-jun gene
transcription that occurs within 30 minutes of extracellular stimuli. Although the
exact mechanism is unclear, studies suggest that the immediate decay of c-Fos
proteins contribute to low levels of Jtrn/Fos heterodimers, which in turn reduce
c-jun gene transcription, and diminish the activation of AP-1 target genes. The
c-jun message also has inherent destabilizing properties:

the 3' end has the

sequence, AUUUA, which contributes to early mRNA degradation. Moreover,
the message also has an unusually long GC-rich 5'-untranslated region that
reduces its translational effidency.

Kinetic studies show that although TPA

treatment induces a 15 fold increase in c-jun mRNA levels, only a 3 - 4 fold
increase in protein synthesis is observed.

Finally, the c-Jun protein has PEST
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regions (proline, glutamic add, serine, threonine) known to enhance protein
degradation. Recently, the delta region of c-Jun has been linked to ubiquitin
mediated degradation (63). These destabilizing factors, in combination with
necessary post-translational requirements for dimerization and DNA binding,
restrict c-Jun activity to critical events in the cell cyde.

It follows then, that

deregulated c-Jun activity leads to cell transformation.

Overexpression of v-Jun induces cell transformation in CEF.
Extensive studies from our laboratory and others report that deregulated
overexpression of v-jun induces a rapid and effident cell transformation of CEF
in vitro (3, 4). The fibroblasts appear transformed by two important criteria:

loss of contact inhibition and anchorage independence.

In addition,

these

phenotypic properties dosely resemble ASV-17 induced tumors in chickens (3,
35, 37).

In contrast,

overexpression of c-jun transforms CEF weakly when

compared to v-jun (10-25 fold less) (4,32), and fails to form tumors in chickens
(30). Intriguingly, Jim transformed CEF are not immortalized; instead, they
become vacuolated after 25 to 30 cell doublings, and die. Possible differences
exist between mammalian and avian systems: the former requires a cooperating
Ha-Ras oncogene for effident cell transformation (35).

The mechanisms involved in the Jun induced cell transformation of CEF
are not clearly defined. A working model proposes that the structural alterations
in v-Jun

affect its functional properties,

as exhibited by an increase in its

transformation potential. These points will be discussed below.
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Structural alterations in Jun protein affect its functional properties.
The structural differences between c-Jun and v-Jun are shown in figure 1.
v-Jun has a gag leader sequence obtained from the transforming retrovirus, a 27
amino a d d deletion at the amino terminus that maps to a transactivation
domain,

and

contains three point mutations at the carboxyl terminus (35).

Studies show that deletion of the 27 amino a d d region (called the delta domain)
is critical to v-Jun's transformation potential (4, 5,70). The delta domain contains
regulatory sequence information influendng Jun stability (63), DNA binding,
dimerization (58), trans-activating properties, as well as its translocation to the
nudeus (75). In addition, loss of the delta region affects the ability of specific
kinases, such as JNK/ SAPK, to effidently phosphorylate Jun proteins in vitro
and in vivo (39). Deletion also increases v-Jun’s half-life by redudng ubiquitin
mediated degradation (63).

Consequently,

post-translational modifications

responsible for appropriate stringent control are lost, contributing to a stable,
unregulated v-Jun protein. Although c-Jun possesses no structural defect, weak
transformation still occurs since expression from the retroviral LTR, maintains
high levels of c-Jun,

thus prolonging its activity (4).

Taken together,

differences in transformation potential between c-Jun and v-Jun,

the

can be

explained, in part, by their structural differences, namely loss of the delta
region in v-Jun.

Dimerization affects Jun transforming ability.
During normal physiological conditions,

the half-life of potential Jun

heterodimer combinations is low, and restricted to the Go to Gi transition phase
in vivo (67). Studies estimate that dimerization among the Jun and Fos family

members alone contribute to 15 potential dimer combinations with varying
affinities and spedfidties to AP-1 sequences in vitro (22). Although the estimated
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number of complexes appear high, and may increase since Jim interacts with
other non-leudne zipper factors, the predicted number of complexes at any
given time point is actually lower since Jim proteins are inherently unstable and
turnover rapidly. However, when stable v-Jun proteins are overexpressed, the
half-life and repertoire of potential dimer combinations along the cell cycle
would increase dramatically. It follows that these new complexes would illicitly
regulate their target genes, and ultimately contribute to cell transformation.

Changes in v-Jun functional properties could induce transformation by
inappropriate regulation of target genes.
The mechanisms involved in cell transformation have received much
attention in the scientific community (1). One model proposes that oncogenic
transformation might result from a change in the pattern of target gene
expression mediated by changes in DNA binding or transactivation of target
genes (2). A similar situation could occur for v-Jun induced cell transformation.
Conceivably, overexpressed v-Jun would lead to stable interactions with other
transcription factors, thereby increasing the repertoire of potential transcription
regulators. Such interactions could occur both at the protein and DNA level.
Consequently, cell transformation would arise from the illicit regulation of AP-1
and AP-1 related target genes.

Although there is no evidence that v-Jun behaves this way, studies show
that its cellular homolog does. For example, unregulated c-Jun proteins can
inhibit estrogen receptor activity in human breast cancer derived cells (13). c-Jun
proteins can also interact with a variety of transcription factors both at the DNA
level and the protein level (10-15, 18-20,
regulatory protein, myoD,

23, 51). For instance, the master

interacts with Jun proteins during myocyte cell
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differentiation (14, 15).

Jun/ AP-1 proteins also interact with the thyroid

hormone receptor (18),

and the glucocorticoid receptor complex (11, 12).

Interactions with other factors alter the pattern of target gene expression and
overall cellular response.

For instance,

NF-KB p65 and Jun/AP-1 protein

interactions produce potentiated biological responses (10);

myoD and Jun

interactions affect myogenic differentiation (14).

some of these

Finally,

interactions are regulated by extracellular signals: Dimerization between the NFAT p /c and c-Jun proteins are dependent on calcium and PKC signals,
respectively. The resulting NF/AT complex is required to activate critical target
genes.

Activation of these factors by PKC or calcium alone,

stimulates a

different set of target genes (39).

Problem and hypothesis
The mechanisms involved in Jun induced cell transformation are not
completely understood. One model proposes that the structural changes in vJun contribute to its altered functional properties (4). We test the hypothesis that
such changes influence the pattern of target gene expression (2). Consequently,
several target genes would be activated or repressed inappropriately.

Cell

transformation would result from a change in the balance between potential
oncogenic and tumor suppressor target genes (2). This dissertation therefore
aims to support the hypothesis by identifying potential genes regulated by vJun, and to implicate them in cell transformation.
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Objectives
A detailed listing of the objectives are as follows:

AIM 1: Determine v-Jun target specificity in vitro.
•

construct in vitro AP-1 target sequence mutants;

•

characterize the DNA binding specificity of each mutant AP-1 target
sequence in VJ-1, CJ-3, and RCAS nuclear extracts;

•

determine the transactivation potential of each in vitro AP-1 fragment
in VJ-1, CJ-3 and RCAS cells;

AIM 2: Isolate in vivo target genes associated with v-Jun induced cell
transformation by:
•

•

subtractive hybridization:
•

differential screening of subtracted library;

•

identification of differentially expressed clones;

•

Northern blot analysis to confirm differential nature;

differential display:
•

improve the technique;

•

identification of differentially expressed clones;

•

Northern blot analysis to confirm differential nature;

•

partial DNA sequence analysis;

•

GENBANK database searches;

AIM 3: Characterize clone 4, a gene up-regulated in v-Jun transformed CEF;
•

DNA sequence analysis;

•

GENBANK and SWISS-PROT database searches;

•

generation of full length cDNA clone by 5' RACE;
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AIM 4: Characterize done 15-15, a gene repressed in v-Jun transformed CEF;
•

evaluate the stability of apo-Al mRNA;

•

identify the Jun responsive element on the apo-Al promoter;

•

characterize the Jim responsive element by promotor deletion analysis
and DNA transactivation studies;

•

assess the DNA binding properties of the putative responsive element;

•

speculate on a mechanism for the transcriptional regulation of the
chicken apo-Al gene in v-Jun transformed CEF;
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Chapter II. MATERIALS and METHODS

Table 3.

Primers used in this study

primer
A poA l

sequence shown 5' to 3'
p r im e r s

ApoAl-primer

1

CACTGCTCGTCCCGTGTGAG

ApoAl -primer 2

CCTCCGTCCACTTGGCAGAGAAC

ApoAl-primer 3

GGAGAGGAGATTAAGGAGGGGTCC

ApoAl-primer 4

CTCACACGGGACGAGCAGTG

ApoAl-primer 5

CGGGGAGCTCCTGTTTGCTGAGG

ApoAl-primer 6

GCTCTCCTGCCGCTGCTCCG

17

TAATACGACTCACTATAGGG

primer

SP6 primer

GGATTTAGGTGACACTA T AG

SP6-T

GATTTAGGTGACACTATAGAATACT-11

primer

d if f e r e n t ia l
DD-17

d is p la y

5 '-primer

DD-18 5' primer

p r im e r s
CTGCTCTCA
CTTGATTGCC

DD-20 5' primer

CTGATCCATG

DD-A 3' primer

T12-VA

DD-G 3' primer

T12-VG

V=A,G, or C

DD-T3'

T12-V T

V=A,G, or C

T12-VC

V=A,G, or C

primer

DD-C 3' primer
c lo n e

4

V=A,G, or C

p r im e r s

clone 4 primer B

TACATACAGCTCTCATCCTGCCCGATGTAG

clone 4 nested primer

GTCCGGCCCTTCAGCTGCC

anchor primer

CACGAATTCACTATCGATTCTGGAACCTTCAGAGG

reverse anchor primer

CTGGTTCGGCCCACCTCTGAAGGTTCCAGAATCGATAG

A P -1

p r im e r s
GGGTCTAGAATGACNCATCGGATCCTGCAGGA
GGGTCTAGAATGACTNATCGGATCCTGCAGGA
GGGTCTAGAATGACTCNTCGGATCCTGCAGGA
GGGTCTAGAATGANTTATCGGATCCTGCAGGA
GGGTCTAGAATGACNTATCGGATCCTGCAGGA
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Transformation of chicken embryo fibroblasts
Primary chicken embryo fibroblasts (CEF) were isolated from 9-11 day
old chicken embryos and transformed by infection with a replication competent
retroviral vector, RCAS, designed to overexpress either v-Jun or c-Jun (4, 38).
CEF infected with vector sequences alone do not transform and serve as normal
control. Jun overexpression is verified by Western blot analysis. These cells are
used to isolate nuclear extracts for DNA binding assays, to isolate RNA for
Northern blot analysis, the differential display and subtractive hybridization
approach; CEF were also used for DNA transfection assays.

Generation of mutant AP-1 fragments and reporter CAT constructs.
Sixteen in vitro generated m utant AP-1 sequences containing variations in
the consensus AP-1 site,

were constructed by primer extension of two

overlapping oligonucleotides. Five different oligonucleotides (table 1) containing
a degenerate nucleotide at a single position were allowed to anneal, and were
then extended with Klenow to generate double stranded sequences.

After

restriction digestion, sequences were cloned into pGEM4 vector and amplified in
appropriate hosts. Individual clones were isolated and verified by sequencing.
The overall strategy is described in figure 2. The resulting sequences are shown
in table 4. These sequences are used in a DNA binding assay described below,
and

were cloned upstream from the human metallothionein promotor of a

reporter CAT construct, pMCAT III, for DNA trans-activation studies.

DNA binding assays
DNA binding assays are a modification from Nakabeppu (43). Briefly, 1
to 10 ug of nuclear extracts in a reaction buffer containing 1 u g / uL poly dl-dC
poly dl-dC, 10 mM HEPES pH 8.0, 4 mM MgCk 17.5% glycerol, 0.1 mM EDTA,
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20 mM NaCl, 2 mM DTT, and 2 mM spermidine are pre-incubated on ice for 15
minutes, followed by incubation with 50,000 cpms of labeled probe.

The

resulting complexes formed are separated on a 4-6 percent (59:1) acrylamide/ bis
-acrylamide /TBE gel,

dried,

and exposed to autoradiographic film.

Competition shift assays used a 40 to 100 fold excess of unlabeled homologous
oligonucleotide or specific antibody.

Quantitation of binding intensity is

determined by densitometric scanning.

DNA transactivation
Sequences of interest were either cloned upstream from the human
metallothionein promotor at the Bgin site of the pMCAT 3 construct, or into the
multiple cloning site of the pCAT/Blue construct, which contains the CAT gene
in a pBluescript SK (+)vector. These reporter CAT constructs were transiently
transfected into either v-Jun transformed, c-Jun overexpression or normal CEF
by a DMSO-polybrene procedure (40). Relative transcriptional activation from
these sequences are evaluated by a CAT assay (45); quantitation of CAT protein
expression was done on a phospho-imager (Molecular Dynamics).

CAT

expression was normalized to B-galactosidase activity from the construct,
pCHllO.

Northern blot analysis
Total RNA was isolated from transformed or normal CEF by an addphenol extraction procedure (41). Briefly, CEF are lysed in guanidine-isothiocyanate solution, and extracted with ad d phenol and chloroform. The aqueous
phase containing RNA was predpitated with isopropanol, and rinsed with
ethanol. 10 to 15 ug of total RNA was then separated on a 1 per cent agarose/
formaldehyde gel,

transferred to nylon membrane,

UV-crosslinked at 150
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mjoules/ cm2, and hybridized to a labeled probe at 42 °C for 3 to 4 hours. Excess
probe was removed by several 20 minute stringent washes in 0.1 X SDS / 0.1
%SSC at 42 ° to 60 °C, and exposed to X-ray film for autoradiography (53).

Differential screening of a subtractive cDNA library
Enrichment of unique sequences from a subtracted VJ-1 cDNA library
were accomplished by a Reverse Northern procedure (42). Briefly, 5 ug of
mRNA from v-Jun transformed CEF (VJ-1), c-Jun overexpressing (CJ-3), and
normal CEF (RCAS) were each extended

by reverse transcription using 20

pmoles of SP6 Oligo T primer, in IX RT buffer (BRL) containing 400 mM dNTP,
100 mM DTT, 5 ng / mL Actinomycin D, and 300 units of MoMuRT, at 37 °C for
45 minutes.

The cDNA sequences were converted into double stranded

sequences with Klenow and random hexamers (53). The resulting sequences
contained an SP6 site at one end allowing generation of large amounts of labeled
anti-sense RNA using SP6 RNA polymerase (42, 53). 3,000 colonies from the
subtracted VJ-1 library were poked out into LB plates in quadruplicate. Colony
lifts were prepared from three sets; the nylon filters were UV-crosslinked at 150
mjoules (BioRad UV-crosslinker) and pre-hybridized for 5 hours at 65 °C (53).
Each set of labeled anti-sense transcripts were then hybridized to individual
colony lifts from the subtracted library overnight at 65 °C, washed in stringent
conditions, and exposed for autoradiography (53). Unique colonies hybridizing
to VJ-1 labeled transcripts but not to CJ-3 and RCAS were identified,

and

isolated from the unhybridized set.

Construction of ApoAl promotor CAT plasmids.
All promotor fragments used in the study utilized the pCAT/ Blue
construct generated by inserting the HinDIII/ BamHI CAT gene fragment from
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pSV2CAT plasmid,

into the HinDIII/ BamHI site of pBluesaipt SK (+)

phagemid. The -193/20 fragment was generated by PCR amplification using
ApoAl primer 5 and 1. The -193/20 fragment was generated by digesting the
5/1 PCR fragment with Sadi which removes 20 bases of exon 1. The -300/263
fragment was generated by isolating the 563 bp K pnI/PstI fragment from the
p7.5 ApoAl /Blue construct, which contains the 7.5 kb genomic sequence cloned
into pBluescript. The -300/ 43 fragment was generated by PCR amplifying the p300/263 ApoAl CAT construct with ApoAl-primer 6 and a T7 primer which
hybridizes to polylinker sequences. The -300/20 fragment was generated by
PCR amplifying the p-300/263 ApoAl construct with ApoAl primer 1 and T7
primer. The -3.3/43 construct was generated by inserting the 3.0 kb Asp718
fragment from p7.5 ApoAl / Blue into the unique Asp718 site of p-300/ 43 ApoAl
CAT construct. The -3.3/20 construct was generated by inserting the 3.0 kb
Asp718 fragment into p-300/20 ApoAl CAT construct. The p-300/0 fragment
was isolated from a K pnl/ Sac II digestion of p7.5 ApoAl/Blue. The 3.3/0
ApoAl construct was generated by inserting the 3.0 kb Kpnl/ Kpnl fragment
from p7.5 ApoA l/Blue into the Kpnl site of p-300/0 ApoAl-CAT. The p-6.8/0
ApoAl- construct was generated by ligating the 7.6 kb HinDIII/ Xbal fragment
from p7.5 A poA l/Blue with 4.1 kb HinDIII/ Xbal fragment from p-3.3/0 ApoAl
CAT construct.

Differential display
The modified differential display procedure is described in reference 46.
Briefly, the reverse transcriptase step was accomplished by annealing 0.2 ug of
mRNA with 250 pmoles of unlabeled 3' primer (Table 1) at 65 °C for 5 minutes,
followed by extension at 37 °C for 1 to 1.5 hours. The reaction was terminated
at 90 °C for 3 minutes. The RT reaction buffer contained 10 mM DTT, 0.5 mM
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dNTP, 12.5 ng/uL Actinomycin D and 300 units of Moloney murine Reverse
transcriptase (BRL Gibco).

After the RT reaction,

the RNA template was

removed with 1 ug/m L RNAse A digestion. Excess primers, unincorporated
dNTP and degraded RNA were removed by size exclusion on a Chromaspin-10
column. One fourth of the resulting single stranded cDNA sequences were then
PCR amplified with 20 pmoles 5'-primer and 20 pmoles of end labeled 3-primer,
for 35 to 40 cycles at 94° C / 45 seconds, 40 ° to 42 °C / 2 minutes, and 70 °C /1
minute. The IX PCR buffer (Promega) includes 200 uM dNTP, 1 mM MgCk and
5 units of sequencing grade Taq DNA polymerase (Promega). The PCR products
were separated on a 5% denaturing poly-acrylamide / urea gel, and exposed for
autoradiography. Selected bands were excised, PCR amplified, and sub-cloned
into a PCR cloning vector, pGEM-T (Promega). Differential expression was
verified by Northern blot

analysis.

Selected clones were sequenced by a

dideoxy method using a USB sequencing kit,

according to manufacturer’s

suggestions.

Construction of cDNA libraries and subtractive hybridization
Briefly, three plasmid cDNA libraries were prepared from mRNA isolated
from v-Jun transforming (VJ-1), c-Jun overexpressing (CJ-3), and from normal
CEF (RCAS). To obtain sequences unique to v-Jun transformed cells, a VJ-1
minus RCAS subtraction was performed. Briefly, single stranded sequences
were obtained from RCAS cDNA libraries by phage rescue utilizing dNTP-biotin
incorporation.

These single stranded sequences were then extensively

hybridized with double stranded plasmid sequences from VJ-1 cDNA library,
and separated on a Strep-Avidin column. Common sequences are retained in
the column, while unique sequences elute out, and were packaged for infection
to appropriate hosts. Similar strategies to isolate sequences unique to c-Jun
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overexpressing cells were performed. Plasmid and subtracted libraries were
prepared by Dr. Timothy J. Bos.

DNA Sequence Analysis
DNA sequence analysis was performed by the dideoxy sequencing
method utilizing the USB Sequenase Kit, according to manufacturer's
recommendations.

Table 4. AP-1 a n d ’AP-1 like' sequences used in study.

sequence

description

TGACTCA

consensus AP-1

TGACATCA

chicken jun promotor

TGACGTCA

CREB

TGACTAA

S V40 promotor

TGACTCG
TGACTCT
TGACTGA
TGACTTA
TGACTCC
TGACCCA
TGACCTCA
TGACGCA
TGACACA
TGATTTCA
TGAGTTCA
TGACTTCA
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GG6TCTAGAATGACTCATCGGAXCCTGCAGGA

Anneal

GGGTCTAGAATGACTCATCGGATCCTGCAGGA
AGGACGTCCTAGGCTACCCAGTAAGATCTGGG

*
Xba I

Pst I

Xba I

GGGTCTAGAATGACTC0CGGATCCTGCAGGATCCGATGG6tcATTCTAGACCC
CCCAGATCTTACTGAG^GCCTAGGACGTCCTAGGCTACC£JM;TAAGATCTGGG
BaniHI

BamHI

.
♦

CTAGAATGACTCMCGGATCCTGCA
TTACTGAGjrjvGCCTAGG

Pst I
Xbal

GGATCCGATGGGTCATT
ACGTCCTAGGCTACCCAGTAAGATC

clone into pGEM 4 at
Pst I and Xba I
*

Figure 2

Strategy for generating 16 different AP-1 mutant sequences.

Five different oligonucleotides containing a degenerate nucleotide at a single
position were allowed to anneal, and then extended with Klenow to generate
double stranded sequences. After restriction digestion, sequences were cloned
into pGEM 4 vector and amplified in appropriate hosts, Individual clones were
isolated and verified by DNA sequencing. The (*) indicates residues in the
primer that contained all four nucleotides. Individual primers contained only one
degenerate nucleotide.
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Chapter III.

RESULTS

AIM 1: Determine v-Jun target specificity in vitro.
As mentioned earlier, overexpression of Jun proteins could potentially
increase the repertoire of possible dimer combinations, and consequently alter
the pattern of target gene expression. To evaluate this possibility, the DNA
binding properties of overexpressed Jun complexes formed in vivo against in
vitro generated AP-1 and AP-1 related' sequences were assessed. We wished to

compare our findings with previous studies demonstrating variations in DNA
binding using in vitro translated Jun proteins to in vitro generated AP-1 sequences
(22,52). We also wished to determine the trans-activation potential of these AP-1
sequences in the context of v-Jun transformed conditions and normal conditions,
and correlate them to DNA binding.

We expect to find qualitative and

quantitative differences in target recognition and transcriptional activation
between v-Jun and c-Jun proteins during overexpression. These studies not only
establish experimental conditions necessary to identify in vivo target genes but
will give us an idea on potential regulatory mechanisms involved in

v-Jun

induced transformation.

DNA binding to consensus AP-1 and related AP-1 sequences.
To investigate the DNA binding properties of in vivo Jun complexes,
nuclear extracts from v-Jun transformed,

c-Jun overexpressing,

and normal

CEF, were isolated and used in a gel shift assay to the consensus AP-1 and to the
various AP-1 like sequences. These nuclear extracts represent possible Jun dimer
complexes formed in vivo under those conditions.

Figure 3 shows that the

consensus AP-1 sequence, TGACTCA, is recognized by two distinct complexes
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Figure 3
sequences.

DNA binding to consensus AP-1 and related AP-1

Competition shift assays of related AP-1 sequences against the
consensus AP-1 sequence to in vivo Jun complexes present in v-Jun
transformed (VJ-1), c-Jun overexpressing (CJ-3), and normal CEF
infected with retroviral sequences only (RCAS), were assessed. A 40
to 50 Molar excess o f competitor fragments were used. Arrows show
position of complex 1 and 2. lane positions are:
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

probe alone TGACTCA
no competition
TGACTCA
TGACTCG
TGACTCT
TGACTCC
TGACTTA
TGACTAA
TGACTGA
TGACCCA
TGACGCA
polylinker
TGACACA
TGATTTCA
TGAGTTCA
TGACTTCA
TGACCTCA
TGACATCA
TGACGTCA
polylinker
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present in all three cell types. Interestingly, no significant differences in band
intensity were noted among the three conditions even when Western blot
analysis show that Jun proteins are greatly overexpressed in CEF transformed
with either c-Jun or v-Jun. (Figure 4). This finding suggests that only small
amounts of Jun proteins are required for DNA binding to the consensus AP-1
site, or that much of the overexpressed protein may be inactive.

To determine if other AP-1 related sequences are preferentially
recognized over the consensus AP-1 sequence, sixteen different but related AP-1
sites (figure 2; table 4) were used in competition shift assays (figure 3). The
study

shows marked differences in the ability of each nuclear extract to

preferentially recognize the consensus AP-1 site. Table 5 shows the statistical
analysis of relative DNA binding among the different AP-1 sequences, between
both complexes, and among cell types. Interestingly, the variations occur in the
lower band. While most of the sequences did not compete with the consensus
AP-1 site, five of the sixteen AP-1 like sequences show dramatic differences. This
finding

suggests

that complexes

formed

during

v-Jun

overexpression

preferentially recognize a different subset of AP-1 related promotor sequences,
as compared to the complexes when c-Jun is overexpressed, or to Jun complexes
during normal conditions. Such differences in substrate specificity indicate that
Jun overexpression increases the repertoire of available heterocomplexes, and
consequently affect DNA binding or DNA trans-activation of Jim target genes.
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Day 4

Figure 4

Day 7

Western blot of overexpressed Jun proteins.

Protein from v-Jun transformed CEF (VJ-1), c-Jun overexpressing
CEF (CJ-3), and normal CEF infected with vector sequences alone
(RCAS) were assayed for Jun expression using a Jun specific antibody,
PEP-1. Expression was monitored 4-7 days after infection.
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Table 5

Statistical analysis of DNA binding to AP-1 and AP-1 like sequences.

Relative competition by AP-1 and 'AP-1 like1sequences for binding to specific
in vivo complexes.
CJ-3

VJ-1
c o m p le x
1
TGACTCA

86 +/- 08

RCAS

co m p le x
1

co m p le x
2

82 +/- 04

87 +/-09

89 +/-06

c o m p le x
2

complex
I

complex
2

86 +/-12

93 +/-04

TGACTCG

20 +/-19

18 +/-15

34 +/-25

47 +/-1I

6+/-08

28 +/-12

TGACTCT

23 +/-16

31 +/-18

28 +/-24

36 +1-22

24 +/-12

60 +': |7

TGACTCC

26 +/-16

10 +/-I4

18 +/-07

14 +/-09

9 +/-I2

3 +/-04

TGACITA

5 +/-09

11 +/-10

09 +/-05

15 +/-19

30 +/-13

57 +/-11

TGACIAA

47 +/-14

37 +1-23

56 +/-08

70 +/-14

35 +/-38

50 +Z-36

TGAGCTCA

9 +/-13

13 +/-18

21 +/-07

3 +/-04

10 +/-14

3 +1-04

TGACCCA

9 +/-I3

0 +/-00

12 +1-07

0 +/-00

7 +/-09

26 +/-16

TGACGCA

61 +/-09

60 +/-17

64 +/-I6

70 +/-14

48 +/-30

63 +/-29

TGACACA

41 +/-21

26 +/-19

54 +/-23

66 +/-06

43 +/-26

45 +/-07

TGATTCA

7 +/-11

0 +/-00

15 +/-19

26 +.'-03

10 + /-1 7

32 +/-11

TGAGTI’CA

12 +/-10

14 +/-17

7 +/-09

34 +/-16

9 +/-08

57 +'-09

TGACITCA

12 +/-I7

13 +/-15

7 +12

68 +/-13

15 + -11

76 +/-05

TGACCTCA

17 +/-17

14 +/-13

13 +/-I5

58 +/-03

18 +/-23

68 +/-05

TCiACA’l'CA

48 +/- 22

51 +/-25

50 +/-28

83 +/-07

43 +/-41

82 +/-U

TGACGTCA

80 +/-17

70 +/-28

82 +/-18

96 +/-03

83 +/-11

1(X) +/-07

Significant differences between complex 1 and complex 2 within each cell type are
denoted by boxes. Differences calculated by ANOVA with P = 0.05.

Variations in target recognition by individual complexes between cell
complex 1________

v-Jun
TGACITA

5 +/-09

complex 2

c-Jun

RCAS

v-Jun

c-Jun

RCAS

19 +/-05

30 +/-13

II +/-10

15 +/-I9

57 +/-II

TGACACA

26 +/-19

66 +/-06

45 +'-07

TGATITCA

(X) +/-CX)

26 +/-03

32 +/-1I

TGAG'ITCA

14 +/-I7

34 +/-16

57 +'-09

TGACITCA

13 +'-15

68 +'-13

76 +'-05

TGACCTCA

13 +/-15

58 +/-03

68 +/-05

TGACATCA

51 +!-25

83 +/-07

82 +/-I1

Significant differences were determined by ANOVA with P = 0.05.
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Identification of in vivo complexes that recognize the AP-1 site.
Having demonstrated variability in DNA target recognition among Jun
complexes to different AP-1 related sequences, antibody shift experiments were
performed to identify the complexes present in both bands. Figure 5 shows that
a Jun specific antibody reduces the band intensity of both complexes in all three
cell conditions.

This finding suggests that Jun proteins form at least two

complexes with other nuclear factors resulting in different molecular weight
aggregates. It is interesting to note that in vitro generated c-Jun and v-Jun
homodimers bind DNA very weakly,

and require other dimer partners to

efficiently demonstrate DNA binding. Most likely, Jun proteins require other
nuclear factors to efficiently trans-activate AP-1 target sequences.

Efforts to

identify other Jun partners were also performed. Anti-fra-2 antibodies cause a
super-shift in all three nuclear extracts (figure 5). It is possible that one or both
complexes contain Fra-2 proteins.

DNA transactivation studies.
Having demonstrated that overexpression of either v-Jun or c-Jun
complexes alters the DNA binding pattern to different AP-1 target sequences,
we wished to determine if such differences correlate with transcriptional
activation or repression of these target sequences in the various cell conditions.
To accomplish this,

reporter CAT constructs containing the consensus AP-1

sequences were first tested in a DNA trans-activation study. While noticeable
transcriptional activity occurs from the consensus AP-1 site,

no significant

differences in DNA trans-activation were noted in all three cell conditions (figure
6). This finding is consistent with the DNA binding data from the consensus AP1 sequence,

and indicates that no preferential transcriptional activity occurs

during v-Jun or c-Jun overexpression, or during normal conditions.
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F igure 5
A ntibody S hift C om petition assay
Nuclear extracts from v-Jun transformed CEF (VJ-1), c-Jun overexpressing
(CJ-3), and normal CEF infected with vector sequences only (RCAS) were
used against the consensus AP-1 site. Lane 1: probe alone: TCACTCA;
lane 2: no competition; antibodies used were: anti-Jun polyclonal (3); antiJun PEP1 (4); anti-CREB (5); anti-Fra-2 (6); anti-Fos B (7); anti-Jun B (8);
anti-Fos (9); goat anti-rabbit (10). In vitro translated v-Jun/ c-Fos proteins
were also used against consensus AP-1 site; no competition (A); anti-Jun
polyclonal (B); anti-Jun PEP1 (C); and anti-c-Fos (D). Arrows show
locations o f complex 1 and 2; Dark spot on lane 6 shows supershift using
anti-Fra-2 antibodies.
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Figure 6
sequences.

Transcriptional activation of AP-1 and AP-1 like

Reporter-CAT constructs containing AP-1 and AP-1 like sequences were
transfected into v-Jun transformed (VJ-1, c-Jun overexpressing (CJ-3)
and Normal CEF infected with retroviral sequences only (RCAS), to
investigate their transcriptional responses. This figure shows the results
from the CAT assay. All AP-1 sequences were cloned pMCAT-3
construct, which contains the human metallothionine promotor; junCAT construct contains the jun promotor; lane descriptions are:
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane
lane

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

TGACTCA
TGACTTA
TGACTGA
TGACTCT
TGACTCC
TGACGCA
TGACACA
TGACTCG
TGACTAA
pMCAT-3
j un-CAT
TGACCTCA
TGACTTCA
TGAGTTCA
TGATTTCA
TGACTCA
TGACCCA
TGACATCA
TGACGTCA
pMCAT-3
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When the m utant AP-1 sequences were tested for transcriptional activity
in the 3 cell conditions, the responses produced were below background levels
(figure 6). While these observations are difficult to interpret since the flanking
sequences dose to the AP-1 site greatly affect its transcriptional potential (22), it
is conceivable that a majority of the overexpressed Jun complexes are inactive,
or that DNA binding to these mutant AP-1 sequences results in transcriptional
repression.

In summary, we show that overexpression of v-Jun proteins results in a
change in substrate specifidty in vitro. It is conceivable then that a corresponding
change in the pattern of target gene expression occurs in vivo. For this reason,
we chose to identify potential target genes induced during v-Jun transformation.

AIM 2: Isolate in vivo target genes assodated w ith v-Jun induced cell
transform ation.
Two approaches to identify genes induced during v-Jun transformation
are differential display and subtractive hybridization. Both strategies utilized
mRNA obtained from v-Jun and c-Jun transformed CEF, as well as from normal
CEF.

mRNA from c-Jun expressing cells are induded to characterize

transformation assodated genes from the weakly transforming c-Jun gene. CEF
are chosen in this study since they are effectively transformed by the v-Jun
oncogene without cooperation from other cytoplasmic oncogenes.

This is

significant since other cooperating oncogenes could potentially activate another
distinct set of target genes complicating analysis (36).
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Three potential target genes were isolated by subtractive hybridization.

Using the subtractive hybridization approach,
genes were isolated.

Clone 4

three potential target

is a 700 bp clone showing consistent over

expression in v-Jun transformed CEF over normal CEF. Northern blot analysis
from 5 separate RNA preparations show a 3 to 7 fold increase in steady state
mRNA levels (figure 7).

DNA sequence analysis and GENBANK database

searches show strong homology to a cysteine thiol protease, (see further details
in Aim 3.)

Clone 943 is a 2.2 kb clone that appears to be differentially expressed in vJun transformed CEF by Northern blot analysis (figure 7). Recent experiments
however, show variability in the level of gene expression, perhaps due to
different cell growth conditions, or different stages in the progression of cell
transformation. Further studies to address this are under investigation. Partial
DNA sequence information for clone 943 using SP6 and T7 primers is shown in
figure 8. GENBANK database searches do not show homology to any known
genes.

Clone 15-15 and 14-67 are two of several clones obtained by differential
screening of a subtracted v-Jun cDNA library.

Northern blot data from 5

different RNA preparations show a consistent 3 to 10 fold higher level of clone
15-15 expression in normal CEF over v-Jun transformed CEF (Figure 7). DNA
sequence analysis show that both clone 15-15 and 14-67 are identical. GENBANK
database searches show strong identity to a previously isolated chicken
Apolipoprotein A1 gene, (see further details in Aim 4.)
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V

C

R

clone 4

clone 943
V C R

clone 15-15
V C R

clone 14V

Figure 7

V C R

V C R

clone 103V

Northern blot analysis of v-Jun target genes

Northern blot analysis showing differentially expressed clones 943 and 14V;
overexpressed clones 4 and 103 V; and a repressed clone 15-15; total RNA was
isolated from v-Jun transformed CEF (V); from c-Jun overexpressing cells (C);
and from normal CEF infected with vector sequences only (R).
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5'

TGAGTGTTTCCTGAATAAATGGACACAGAAATAGAAGGATTGAATATTG
TACCCAATTGGTTTTGAATTTAACCTATTTGCTAGGCTTTTACAGACAG
ATCAGGACAAACAGCACTTAAATAAATCTACAGASTGCAAAACAATAAT
GVAAMMAGTGAGCAGAGATAGCTTACYTSGHYGATGAATGMACCATSCA
CMCTTTTGCGACGTTTCATGTAATTGCTTTTCCTCTCCGGTCATTAAGA
ACMGAAATGTTCCAACTGGCTTTAGGTATGAGATTTTTATTGTTATTTT
AAATTGCCAGTTGTTGGRGATCAGATATTGAGTGCMGTCAGCACTGGAG
TTCCTCTCTGCTTTTWTGTWGATAAACAAATATATCTWGATATCCTTGT
AGTATGCTCTTATCTGTTGGAGTTGCACAGCAGTGGTGTGATGCTGCGT
GCTCCTGCCCTAAACATACAGAACAAGTGCTCTGCACTCCCCAGAGGGC
TGCAATGGGAAGGGACTTAATTGTACTGGGTGTCTTCTGGGTTACATCC
CTCTGTTTTTCACTCCTGCTTTGTGGATCGAATTTYCTAAGTAGAAAAA
CAGGGGAAAGGAGCAGGTGACTCTTGCTGGGAAWTGTAGCAGAGAATAC
TTATTTCTANYTCTWGATYTAAGTWCAMTYTGATTACTYHDB?AGAGTT
TGGATACAYBCATGCAAATTAAAGAWTTAAACTAAATCTGATAAACTGT
CTGTGTGATTGTAGGCTCTGGSCARGGGTGAGGGGGAAATACCTTTAAC
CTAGAAAGCTTGAYRSMTWKYTWSAGTATTCTAT-------------------------/ / -------------------------------------------------------------------

TCTGAATGAAAGGATCACAGCAACAAMCTCACAAGTGTATTTTATCCTG
CAGCTGGTAATATTTGGGACMAAGGTCTAAGGTGCTGACTTTACCAAAA
ATGGTAGACAATGATAGATACCAGCAAMWTRDAGGCAGCTT?GAAGAGA
ATTTCATATGRACTGGCAGCGCTAAACGTGTRGAAAATWTATAAATCST
TTRRGSARGAAWTTAAACTCTTTTAAAATGAGGGAAATAAAACTGTTTT
CTCATGAAACATTACAACCACTTGGCCTTTCTGTTCCCTTTGGTGCAGA
GCTGTGTTGCTTAGGAGGGGCTCCACTGGCTCACTCATTGAAAGGCCCA
GTGTTCCTGAAGTACATTGCCACTGATGTCAATGAGAGCAGAAGCAAGT
CAGAAACGATGCAAAGAGAAAGTTAAGCAAAGTTGTGAAGAGCTCAGCT
TCTGCCAACAGAACAACAAACAATCTGGGTTGTGTTAAACTCATGTCTG
GTGSCTTATTTCTGCSWACATTACTAGATGAAACATCWTCMARGTGGCT
TAAGATGCAAAGTTTTCATTTCTTTATGGTCTACAGCTGATAAGAGCAT
ACCTTTAGATAATACTGTTTTCAGCCMTGGTTGCTCCBTAWTTTCWAAT
BCATGTTCCTCTYCYTCCCCACAAAGGACCAGCAACACTTTGGCATTTT
TCCTGTTDTCCCACCAAATBGTGTTCCCATTTTCCAATTTGTGTGCCAA
ATTGAAATGACAATTCTATNAAATAAAACCTCTGAAAAAATAAAAAAAA
AAAAAAAAAAAAAAA
3’

Figure 8.
P artial sequence fo r clone 943.
DNA alp h ab et: A=Adenosine; C=Cytidine; G =Guanosine; T =Thymidine;
R =A o rG ; Y = C o rT ; N = G ,A ,T ,o r C ; B = C ,G ,o rY ,n o tA ; D =A, G or
T, not C; H,=A, C, or T not G; V =A, C, or G not T; K=G or C; M =A or C;
S =G or C; W =A orT ;
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Differential display
As an alternative to the conventional subtractive hybridization strategy,
the differential display approach (25-27),

was exploited to identify genes

associated with v-Jun induced cell transformation. The flow diagram in figure 9,
highlights the important aspects of this technique. In this approach, mRNA or
total RNA is extended by a reverse transcriptase reaction (RT) utilizing 1 of 4
types of 12 to 14-mer 3’-primers (table 1). These 3' primers have sequences
complementary to the polyA tail of mRNA, and terminate with a degenerate
penultimate base and specific base. These features are designed to accommodate
all 4 possible 3' end combinations of the poly-A tail, to anchor specifically at the
poly-A tail sequence, and to extend towards the 5' end of the mRNA sequence.
The resulting single stranded cDNA fragments are then labeled by PCR
(polymerase chain reaction) amplification utilizing the same 3' RT primer, and a
5' randomly generated 9 to 12-mer oligonucleotides (table 1). Both primers have
identical annealing temperature. Labeling of PCR fragments is accomplished by
either 32p_dNTP incorporation,

or by 3-kinased primer incorporation.

This

process can be repeated using mRNA from several populations or cell
conditions. The resulting RT-PCR products from several cell population are
separated side by side on a denaturing poly-acrylamide gel able to resolve up to
one base pair difference among sequences, and exposed for autoradiography.
Since each band represents a potential individual gene sequence amplified by a
distinct PCR primer set, unique sequences present in one cell treatment can be
distinguished from sequences common among cell treatments based on their
length and location on the gel. Due to the randomness of the 5' primer, the
procedure can be repeated several times with different 5’ and 3' primer
combinations. Following autoradiography, the differentially expressed bands
are excised, eluted, PCR reamplified, and cloned into a PCR vector. This
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' AAAAAAAA
1AAAAAAAA
AAAAAAAA
AAAAAAAA

reverse transcriptase reaction

PCR amplification

separate PCR products on a
denaturing poly-acrylamidc gel

R

use PCR fragment as a probe in Northern blot
elute out selected
bands and PCR
amplify

Figure 9

analysis, and for isolating full length cDNA
clones from a cDNA library.

Differential display strategy.

This figure shows the flow diagram for the differential display strategy. In
this modified procedure, a kinase end labeled primer (shown as a dark
spot) is utilized for labeling fragments in the PCR step. This modification
greatly enhances the banding pattern and decreases the chance of isolating
false positives, (reference 46).
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cloning step guarantees that characterized sequences are generated from a single
clone. The sequences will be used as a probe in a Northern blot assay to confirm
differential expression. Positive sequences can then be used to select a full length
clone from a cDNA library. This strategy has proven successful in identifying
differentially expressed clones (24).

Advantages
The differential display method has several advantages over conventional
subtractive hybridization. For instance, sequences from several cell populations
or treatments can be compared and identified simultaneously, whereas only two
comparisons are possible with the latter.

Furthermore,

both activated and

repressed gene sequences can be identified by the differential display method
concurrently, while the later will require several subtractive strategies. A major
determinant in the success of the differential display approach depends on the
fortunate selection of the 5' primer.

Using comparisons among normal,

metastatic and tumorigenic cell biopsies, others have identified several genes
including a potential tumor suppressor, the alpha integrin gene (24).

Limitations
A potential problem arising from the differential display strategy is
random misincorporations and mispriming in the PCR step resulting in an
anomalous banding pattern. Optimal PCR conditions require specific 18 to 25 bp
primer sequences with high annealing temperatures of 60 to 65 °C, a 20 to 200
uM dNTP concentration, and a minimum number of amplification cycles: 25 - 30
cycles. However, the PCR parameters described in differential display involve:
[1] a low annealing temperature of short 10-12 m er PCR primers at 40 °C in
asymmetric proportions, [2] a low dNTP concentration of 2 to 4 uM, and [3] a
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high cycle num ber of 40 cycles. While short primers are necessary to reduce the
number of 5' primers required to accommodate all possible primer pair
combinations,

these

parameters

contribute

to

non-specific

template

amplification and further complicate the high error rate and infidelity of Taq
DNA polymerase.

The low dNTP concentration containing

unfortunately generates incomplete extension products.

32p dATP

In our experience,

utilizing only one random 5' primer without a 3' primer can generate extension
products and PCR amplification fragments that contribute to a high background
or false differential banding pattern. Furthermore, DNA sequence analysis of
one differentially selected band consisted of several comigrated sequences
having identical molecular weight or num ber of base pairs. In a recent report on
the differential display technique, Pardee acknowledges that only 20% of the
"differential bands"

characterized are authentic differentially expressed

sequences (27).

Modifications
To overcome the limitations of the differential display strategy, several
modifications were implemented. First, to optimize the reverse transcriptase
reaction, mRNA was selected as a starting template, since potential hairpin loop
extension could occur from tRNA or rRNA present in total RNA. Actinomycin D
was included to prevent hairpin loop extension from mRNA secondary
structure.

After the RT reaction,

the resulting products were treated with

RNAse to remove the RNA template,

and size selected by column

chromatography to obtain longer cDNA extension products,

and remove

unincorporated nucleotides and primers. Second, the labeling procedure in the
PCR step was improved by utilizing a 3'-end labeled primer and a non-labeled 5'arbitrary primer. Since the 3'-primer is in the same sense-orientation as the
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cDNA template, labeled extension can only occur from a 5' extension sequence,
after the second amplification cycle. In this way, a majority of PCR amplified
sequences labeled occur from 3’-primer incorporation. This strategy has several
advantages over the recommended 32p-dATP incorporation. Labeling by 3'primer extension eliminates detection of PCR products generated from two 5'primers in opposing orientations, and detection of false 5'-primer extensions.
Third, PCR conditions were optimized. For example, a DNA Taq polymerase
without 5'-phosphatase activity was selected.

Nucleotide

and primer

concentrations were adjusted to prevent random misincorporations obtained
from low dNTP concentrations.

Figure 10 shows the improvements from labeling by 3'-primer extension.
Notice that the banding pattern in lane 1 using both 5' and 3' primers with 32p_
dNTP incorporation and has an identical pattern to lane 2 using only a 5' primer.
These observations suggests that 32p-dNTP labeling can lead to false priming
events in the PCR reaction, and possible isolation of several false positives. In
contrast,

the modifications described above results in a "cleaner" banding

pattern (figure 10; lane 9). These modifications have been reported (46).

Two potential target genes were isolated by the differential display strategy.
Using the modified differential display strategy,

two potential target

genes were isolated from three cell conditions: mRNA from v-Jun transforming,
c-Jun overexpressing, and normal CEF. Clone 14V and 103V are approximately
250 base pair fragments that shows weak differential expression in v-Jun
transformed cells (figure 7). Partial DNA sequence analysis is shown in figure 11.
GENBANK database searches do not show homology to any known genes.
Clone 4 and 15-15 were chosen for further investigation in AIM 3 and AIM 4.
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Figure 10.
Differential display improvements showing the advantages of
using a 3 ' end labeled primer. T=total RNA; M=mRNA;
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clone 14V
5'

TTTAACACTATGATCTAAGGTATAGATAAATTTGTCCGATG
TGGTTGGTTTTGGGGCACTGAGTCCCGCCCCAGATTGTTTA
AGGTGAGAGGAGAGGCATGT-----------------/ / ---------------TAATATCTCTAAGACATACTGATGCTCTGCTCTACTAAAAT
CTGGCGGACTAGTGCCAAAACCAACCACATAGGACAAAATT
TATCTATAACCTTGAGATACATGAGTGTGGAAAAAAAAAAA
AAAAGATTGG
3'

clone 103V
5'

TGAGGGCAAAAGAATCTTCCAGAGCATCAGTTCTCAAATG
AAAGGGAACTTCACACTCCAGAGGTAGCAGAATGTTTTGA
TGAATATCTATGTAGATTCAAAAGAGAAGTCAGAACTCTG
ACATTAGAGAAGTAGAA--------- / / --------- GAGTGAAAGA
AGAAGCTAGAACTCTGAACAATATAAAGAAGAAAGTAAGA
ATTCTTCTTCCGGCCAGAAAGAAANAGAACTGGCTCAAAG
AAAAANAAGAAGAGGAATAAAAATAGT----- 3'

Figure 11

Partial DNA sequence for clone 14V-5 and 103V-5.

This figure shows partial DNA sequence information for two sequences
isolated by differential display. The 5' and 3' orientations are based on
locations poly A rich regions. More DNA sequence analysis is essential
to confirm these sequences.
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AIM 3: Characterize clone 4, a gene up-regulated in v-Jun transformed CEF.

Clone 4 belongs to a family of related cathepsin proteases.
Clone 4 was identified by subtractive hybridization.

Northern blot

analysis demonstrates its differential expression in v-Jun transformed CEF
(figure 7). Further screening of the v-Jun subtracted cDNA library with a clone 4
probe,

identified two longer cDNAs:

4-572 and 4-768.

Figure 12 shows

overlapping DNA sequence information aligning the new clones with Exo HI
digested fragments of clone 4.

The consensus DNA sequence for clone 4 is shown in figure 12.
GENBANK database searches reveal strong nucleotide sequence homology
between clone 4 and Homarus Americanus (American Lobster) cysteine-thiol
protease. SWISS-PROT database searches using all six reading frames show
significant homology to 34 known protease sequences (table 6).

Amino a d d

alignment between done 4 and cathepsin L proteins from different spedes show
significant

homology to the active site of these thiol proteases (figure 13).

Altogether, these observations strongly suggest that done 4 belongs to a family
of related cysteine-thiol proteases. This finding is significant since a known c-Jun
target gene, stromelysin, is a known protease. Interestingly, clone 4 is novel,
and shows no DNA or amino a d d sequence identity to any known chicken
cathepsin thiol protease.

A doser analysis of the clone 4 cDNA sequence reveals that the 5’ end of
the gene is missing,

since a good open reading frame is not available.

Moreover, protein sequence alignment of done 4 w ith Cathepsin-like proteins
suggests that a portion of the cysteine thiol active site is missing from the NH3
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F i l e Name
4 (3 -6 )
4 (3 -3 )
4 SP6
4 (3 -4 )
4 -7 6 8 -sp 6
4 -5 7 2 -S P 6
4 T7
4 (1 )
4 -7 6 8 -T 7
4 -5 7 2 -T 7

1 43

286

429

572

--------»

716

/

/

O b je c t

GCGGCTCCTG-TTGGGCGTTC-AGCTCAGTGG-GGGCTCTGGA— 40
GGGGCAGCTG-AAGGGCCGGA-CGGGGAAACT-GCTGTCCCTC— 80
AGCCCCCAGA-ATTTGGTGGA-CTGCGTCTCC-AACAACAACG— 120
GCTGCGGGGG-GGGTTATATG-ACCAACGCCT-TCGAATACGT— 16 0
CCGCCTTGAA-CCGCGGCATC-GACTCGGAGG-AYSYGTACCC— 2 0 0
CTACATCGGG-CAGGATGAGA-GCTRTATGTA-CAGCCCCACC— 240
GGAAGKCGGC-CARATCGGCK-ACGGMKATCC-GRGAGATCCC— 28 0
CGAAGCAACG-AGAAGGCTCT-GAAGCGCGCG-GTGGCCCGGA— 320
TTCGCCGGGT-CTCGGTGGGC-ATCGATGCAG-TCTGCCCTCC— 360
TTCCAGTTCT-ACAGCCGCGG-GGTGTACTAC-GACACGAGCT— 40 0
GCAACCCGGA-GAACATCAAC-C ATGCGGTGT-GGCGGTGGGG— 4 4 0
TACGGCGCAC-AGAAGGGCAC-CAAGWCACTG-SATCATCAAG— 4 8 0
AACAGCTGGG-CACGAGTGGC-AATAAGGCTA-CGTGCTGCTG— 520
ACCGCATATG-ACAAGCTGCG-CATGCACCTG-CCAGCTTCCC— 560
CAAGATGTGW-GCTCTGGAGG-TGCCAACGTC-CGTCTGCAGG— 6 0 0
AGTGGGGTTG-GGGGGCTGSA-ACCCCCCCCC-CCCCCCRRRT— 64 0
ATCACATCTC-TGAGTCCWWW-GGGGGGATGC-GGAGAACGAT— 6 8 0
GGGATTTTGT-TCTTCAAATA-AAAGCAGTGG-GGGAGA
— 716

Figure 12.

Partial DNA sequence for clone 4.

Shown above is the sequence alignment o f clone 4 with two longer cDNAs
clones: 4-572 and 4-768, obtained by further screening the v-Jun subtracted
library The consensus sequence is shown below.
DNA alphabet: A=Adenosine; C=Cytidine; G=Guanosine; T=Thymidine;
R = A o rG ; Y = C o rT ; N=G,A, T, o rC ; B=C, G, or Y, not A; D=A, G o r T,
not C; H,=A, C, or T not G; V =A, C, or G not T; K=G or C; M =A or C; S
=G or C; W =A o rT .
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Table 6

SWISS-PROT database search for clone 4

Listing of entries in the SW ISS-PROT database showing strongest
homology to clone 4 amino acid sequence. Note that all entries belong to a
family of proteases from various species.

en tr y
ALEU HORVU
CATB BOVIN
CATB HUMAN
CATB MOUSE
CATH HUMAN
CATH RAT
CATL CHICK
CATL HUMAN
CATL MOUSE
CATL RAT
CATS BOVIN
CATS HUMAN
CATS RAT
CYS1 DICCI
CAS1 HOMAM
CYS1 HORVU
CYS2 DICDI
CYS2 HOMAM
CYS3 HOMAM
CYS4 BRANA
CYSL LYCES
CYSP PEA
CYSP PLAFA
CYSP THEPA
EUMI EURMA
LCPA LEIME
MMAL DERPT
ORYA ORYSA
ORYC ORYSA
P 3 4 SOYBN
PA P2 CARPA
PA P3 CARPA
PA P4 CARPA
PAPA CARPA

nam e
THIOL PROTEASE ALEURAIN PRECURSOR
CATHEPSIN B
CATHEPSIN B PRECURSOR
CATHEPSIN B PRECURSOR
CATHEPSIN H PRECURSOR
CATHEPSIN H PRECURSOR
CATHEPSIN L
CATHEPSIN L PRECURSOR
CATHEPSIN L PRECURSOR
CATHEPSIN L PRECURSOR
CATHEPSIN S
CATHEPSIN S PRECURSOR
CATHEPSIN S PRECURSOR
CYSTEINE PROTEINASE PRECURSOR
DYGESTIVE CYSTEINE PROTEINASE 1
CYSTEINE PROTEINASE EP-B 1 PRECURSOR
CYSTEINE PROTEINASE 2 PRECURSOR
DIGESTIVE CYSTEINE PROTEINASE 2 PRECURSOR
DIGESTIVE CYSTEINE PROTEINASE 3 PRECURSOR
CYSTEINE PROTEINASE COT 4 4 PRECURSOR
LOW TEMP INDUCED CYSTEINE PRECURSOR
CYSTEINE PROTEINASE 1 5 A PRECURSOR
THROPHOZOITE CYSTEINE PROTEINAS PRECURSOR
CYSTEINE PROTEINASE PRECURSOR
MITE GROUP 1 ALLERGENIC PROTEIN
CYSTEINE PROTEINASE PRECURSOR
MAJOR MITE FECAL ALLERGENIC PRECURSOR
ORYZAIN ALPHA CHAIN PRECURSOR
ORYZAIN GAMMA CHAIN PRECURSOR
P 3 4 PROBABLE THIOL PROTEASE PRECURSOR
CHYMOPAPAIN PAPAYA
CARICAIN PAPAYA PRECURSOR
PAPAYA PROTEINASE IV
PAPAIN PRECURSOR
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c 4 AA s e q
CATL_RAT
CATL_MOUSE
CATL.HUMAN
CATL_CHICK

MTPLLLLAVL
MNLLLLLAVL
MNPTLILAAF

CLGTALATPK
CLGTALATPK
CLGIASATLT

FDQTFNAQWH
FDQTFSAEWH
FDHSLEAQWT

QWKSTHRRLY
QWKSTHRRLY
KWKAMHNRLY

GTNEEEWRRA
GTNEEEWRRA
GMNEEGWRRA

50
50
50

c 4 AA s e q
CATL_RAT
CATL.MOUSE
CATI HUMAN
CAT! CHICK

VWEKNMRMIQ
IWEKNMRMIQ
VWEKNMKMIE

LHNGEYSNGK
LHNGEYSNGQ
LHNQEYREGK

HGFTMEMNAF
HGFSMEMNAF
HSFTMAMNAF

GDMTNEEFRQ
GDMTNEEFRQ
GDMTSEEFRQ

IVNGYRHQKH
VVNGYRHQKH
VMNGFQNRKP

100
100
100

c 4 AA s e q
CATL_RAT
CATL.MOUSE
CATI HUMAN
CATI CHICK

- ------------- -------------- -------------KKGRLFQEPL MLQIPKTVDW REKGCVTPVK
KKGRLFQEPL MLKIPKSVDW REKGCVTPVK
RKGKVFQEPL FYEAPRSVDW REKGYVTPVK
— APRSVDW REKGYVTPVK

GSCWA
NQGQlCGSCWA
NQGQiI GSCWA
NQGQii :g s c w a
DQGQCGSCWA

F ;s 11ii iLEGC
F 5A >iii IE G C
F SA |(
F >;<a n1.1LEGC
ETH• 1LE G C

15
150
150
150
37

c 4 AA s e q
CA TL.R A T
CATL.MOUSE
CATL.HUMAN
C A T L .C H IC K

LKGRTf
MFLKT 11
MFLKTfcl
MFRKT
HFRTK

c 4 AA s e q
CA TL.R A T
CATL.MOUSE
CATL.HUMAN
C A T L .C H IC K

AYPYIGQDESjYPYfAKDGSYPY AKDGSYPYI ATEESYPY' AKDDE

O Y 5 P R -S R
( KYIAEYAV
( KY LAEFAV
$ ( KY JPKYSV
C FY (AEYNA

c 4 AA s e q
C A TL.R A T
CATL.MOUSE
CATL.HUMAN
CATI— CHICK
c 4 AA s e q
CA TL.R A T
CATL.MOUSE
CATL.HUMAN
CATI CHICK

Figure 13.
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DSED
KEN itLDSE
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QDN j i ;d s e
QDN E?: :d se

NRLPRSRGYR
ANDTGFVDIP
ANDTGFVDIP
ANDTGFVDIP
ANDTGFVDIP

ElR A TR R LX
Q- |l KALMKA
Q - \\ KALMKA
K- *1 KALMKA
QG« RALMKA

[SpRWPGFAGR
VVTVGPISVA
VS\TVGPISVA
VStTVGPISVA
\SVGPVSVA

111
248
248
248
137

WASMQSALLP VLQPRGVRHE
MDASHPSLQF YSSGIYYEPN
MDASHPSLQF YSSGIYYEPN
IDAGHESFLF YKEGIYFEPD
IDAGHSSFQF YQSGIYYEPD

LQPGEHQPCG
CSSKDLDHGV
CSSKNLDHGV
CSSEDMDHGV
CSSEDLDHGV

VWGYCAQKG
LMGYCYEGT
L.VGYCYEGT
LfVGYCFEST
L (VGY(FEGG

'I SPGS
DSNK» YWLV
DSNKNI :y wlv
ESDN YWLV
— - YWIV

157
298
298
298
183

SRTA »i IEH■Q
KNSW mi;e' CM
KNSW m: £1CM
KNSW mLB'ICM
KNSW mI :Kt QD

KLR
M
NNHCGLATAA
DNHCGLATAA
RNHCGIASAA
KNHCGIATAA

H
S
S
S
S

LVDCi
QNLVDCf
NLVDC:

) GY / LLTAYD
I GY ElKIAKDR
qGY ClKIAKDR
(GY/I KMAKDR
KGYtr YMAKDR

f l —

IVN
VVN
TVLV-

63
200

200
200

87

183
334
334
333
218

Alignment of clone 4 to several Cathepsin L proteases.

Shaded areas are regions of strongest homology between clone 4 and family of
Cathepsin L proteases. Dark line show the cysteine thiol protease active site
having the consensus sequence: QXXX[G/E1XC W XX|STAG ].
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700 bp seq of clone 4

Pvu I
//

AAAAAAAAAAA

reverse transcribe mRNA from v-Jun
transformed CEF with clone 4 primer B

ligate cDNA to anchor
primer with RNA ligasc

LicoR I

PCR amplify with 5' reverse
anchor primer and nested primer

licoR I

Figure 14.

Pvu 11

s'-RACE strategy used to determine the S' end of clone 4.

RACE Rapid Amplification of Cloning Ends: mRNA isolated from v-Jun
transformed CEF is reverse transcribed with primer B which is
complementary to the 5' terminal region of clone 4. The resulting fragment is
then ligated to an anchor sequence with RNA ligase, and PCR amplified with
a nested primer complementary to sequences upstream from primer B, and a
reverse anchor primer. The resulting PCR fragment can be verified by DNA
sequencing and restriction analysis. The convenient restriction sites in the
anchor sequence and PCR fragment can be used to generated a full length
sequence.
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terminal region (figure 13). To obtain the 5' end of the gene, a 5' RACE (Rapid
Amplification of Cloning Ends) strategy was attempted (figure 14). A full length
clone can easily be constructed utilizing convenient restriction sites.

AIM 4: Characterize clone 15-15.

Clone 15-15 was isolated by differential screening a subtracted v-Jun
cDNA library and shown to be preferentially expressed in normal CEF. DNA
sequencing and GENBANK database searches show strong sequence identity to
the chicken apolipoprotein A -l gene. Clone 15-15 was therefore chosen for study
since its identity is known,

and the regulatory mechanisms in mammalian

systems were well characterized.

Previous studies
Apolipoprotein A1 (Apo-Al) is the major protein constituent of high
density lipoproteins (HDL).

Early studies suggest that these proteins are

responsible for overall cholesterol metabolism, transport and distribution, and
play an important role in reducing coronary heart disease (47 and references
dted).

The apo-Al gene is highly conserved in several species; the rat, human
and chicken genes show strong sequence homology in the 5’ regulatory region
and coding areas. While mammalian apo-Al expression is restricted to the liver
and intestine, avian species express it in all tissues, although predominantly in
liver and intestine. Appreciable amounts are detected in kidney, ovary/testes,
brain, lung, skeletal and heart muscle. Furthermore, males express higher
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levels of Apo-Al protein in comparison to females. These findings suggest that
different regulatory mechanisms exist among species and within different tissue
environments (47).

The regulation of the apo-Al gene at the transcriptional level has received
much attention.

The mammalian apo-Al regulatory region contains four

responsive elements (site A, B, C and D) (figure 15). Transcription factors that
recognize site A include a placental transcription factor (ARP-1) and the retinoic
acid receptor (RXRa), which decrease and increase apo-Al, respectively (47,48).
In rat hepatocytes,

a member of the thyroid/ steroid receptor super-family

(HNF-4), positively regulates apo-Al through site C (50). Site B is recognized by
several factors.

Studies conclude that transcriptional regulation of the

mammalian Apo-Al gene is determined by an interaction among several
transcription factors both at the protein level and at DNA binding sites.

site A

site B

site C

site D

s

mammalian

-2 2 0
avian

-2 0 8

-1 8 6

-1 5 8

trrr

-1 2 3

-1 0 8

"■ ■ —

i

-6 0 -5 5

11-

Figure 15. Structure of the ApoAl regulatory region.
This figure shows a comparison between the mammalian and avian
upstream regulatory elements, highlighting the regions of significant
homology.
In contrast to the mammalian regulatory region, the chicken sequences
show no homology to site A, have homology to only half of site B, and strong
homology to sites C and D. Functional analysis of the chicken apo-Al regulatory
region identifies site D (-60 to -54 ) as the positive enhancer element in several
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transformed cell lines, including human hepatoma (HEP-G2), human colon
carcinoma (Caco2),

human cervical epithelial (HeLa),

mouse embryonal

fibroblasts (NIH/3T3), and RSV transformed quail myoblasts (QMLA29) (47).
Although site D resembles a GC rich SP-1 binding site, SP-1 or other factors have
not been demonstrated to recognize this site. Surprisingly, these studies also
show that constructs containing upstream sequences beyond

-300 nucleotides

are weakly fraws-activated in these cell lines.

avian sequences

corresponding

to

mammalian

enhancer

In addition,

elements

A,

B,

and

C

are

transcriptionally inactive (47, 48)). This finding contrasts with another report
showing apo-Al

to be repressed in quail myoblasts transformed with a

temperature sensitive Rous Sarcoma Virus (RSV) at the permissive temperature,
but expressed during non-permissive temperatures (49).

Qearly,

different

regulatory mechanisms exist between mammalian and avian species (47).

ApoAl regulation.
Northern blot analysis in our laboratory suggest that the steady state
levels of apo-Al mRNA are approximately 3 to 10 fold higher in normal CEF, as
compared to v-Jun transformed CEF (figure 7). There are several possibilities.
One explanation is that transcriptional repression occurs in v-Jun transformed
CEF; that is, the transcription rates are slower in v-Jun transformed CEF, as
compared with normal CEF. Another possibility could be that the turnover rates
in both cell conditions are different. Accumulation of a stable apo-Al mRNA
could occur in normal CEF. Alternatively, overexpressed v-Jun proteins could
contribute to unstable apo-Al mRNA in v-Jun transformed cells. With these
questions in mind, we decided to determine how v-Jun directly or indirectly
influences chicken apo-Al gene expression in transformed CEF, as compared to
normal CEF.
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ApoAl mRNA is very stable.

Actinomytin D treatments were used to assess the half-life, and message
stability of apo-Al mRNA during normal and transformed conditions. This drug
blocks transcription by inhibiting RNA polymerase II activity,

allowing an

evaluation of mRNA stability during transcriptional repression. A rapid decay
rate strongly indicates message instability, while a slow decay rate suggests that
high message stability contributes to accumulation.

v-Jun transformed (VJ-1) and normal CEF infected w ith vector sequences
only (RCAS) were treated with 5 ug/ mL of Act D at different time points. Total
RNA was isolated, and the steady state levels of apo-Al mRNA were estimated
by Northern blotting. Although the levels of apo-Al message are clearly higher
in normal CEF (figure 16),

the decay rates in both v-Jun transformed and

normal CEF are identical (Figure 17). This gradual decrease for up to 20 hours
indicates that apo-Al mRNA is very stable in both cell conditions (tl/2 = 15 to 20
hours), and reveals that the differences in steady state levels observed in the
Northern blots can not be explained by mRNA stability. More importantly, the
data suggests the v-Jun overexpression does not contribute to apo-Al message
instability. It is therefore conceivable that the variations in apo-Al message seen
in Northern blot analysis are due to accumulation of a stable message from an
upstream regulatory sequence,
responsible.

or that transcriptional mechanisms are

With these considerations,

we set out to identify potential

regulatory sequences by promotor deletion analysis, and verify them by DNA
binding studies.
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Figure 16.

Actinomycin D studies.

Top figure shows Northern blot analysis of total RNA from v-Jun transformed
CEF (VJ-1) and normal CEF infected with retroviral sequences only (RCAS)
treated with 5 ug/mL Actinomycin D at indicated time points. Bottom figure
shows quantitation of mRNA levels at indicated time points, demonstrating higher
steady state levels of apo-A l message in RCAS than in VJ-1.
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Figure 17

Estimation of apo-Al mRNA half life.

Quantitation of apo-A l mRNA steady state levels in v-Jun transformed CEF
(VJ-1), and Normal CEF treated with retroviral sequences only (RCAS)
after Actinomycin D treatment. Study shows identical decay rates in both
VJ-1 and RCAS CEF. Estimated mRNA half life is approximately 20
hours.
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Isolation of an apo-Al genomic clone.

To determine if transcriptional control mechanisms influence apo-Al gene
expression during normal and transformed conditions, we first isolated the
upstream regulatory region of apo-Al from a genomic done. The 13 kb genomic
clone was isolated by screening a lambda chicken genomic library w ith a 700 bp
done 15-15 sequence as a probe. Restriction analysis, Southern blotting and
partial DNA sequendng verify the authentidty of the genomic done,

as

reported previously. Figure 18 below shows the genomic map of the apo-Al
gene and sequences corresponding to done 15-15.

--10kb —fiftkh

-aakh

kill'

1iniiif—

exon 1

ex o n 2

-nnkh

i

53235353485353484848232353535348482348534848

ex o n 3

ex on 4
1 5 -1 5 se q

Figure 18. Structure of the ApoAl genomic clone.

This figure shows the

ap o-A l regulatory region in relation to its coding region and sequences

corresponding to clone 15-15.

Convinced that an authentic genomic clone was isolated, we set out to search for
potential activator or repressor elements by promotor deletion analysis.
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Promotor deletion analysis.

To identify potential c/s-acting sequences on the apo-Al regulatory region,
several reporter CAT constructs containing 5' deletions were transiently
transfected into v-Jun transformed CEF (VJ-1), and normal CEF infected with
retroviral sequences only (RCAS). A summary of reporter CAT constructs and
corresponding responses are shown in figure 19; the CAT assay is shown in
figure 20.

Studies show three potential cis-acting regulatory elements on the apo-Al
gene. A strong activator region is present between -6800 to -3300 nucleotides.
Deletion of this region to generate the p-3300/0 construct, reduces the level of
expression from 11 fold to background levels in normal cells.

Another

responsive site may be located within 20 bases of exon 1. Exclusion of this site
reduces the level of expression by approximately 1 to 2.5 fold [compare

p-

193/20 to p-193/0; p-3300/20 to p-3300/0 and p-300/20 to p-300/0]. However,
the remaining half of exon 1 (bases 20 to 43) could hold repressive regions.
Addition of these sequences appears to reduce expression by 1.4 to 4 fold;
[compare p-300/43 to p-300/20;
potential repressive region

and p-3300/43 to p-3300/20].

Finally,

a

could be located within sequences -3300 to 300.

Deletion of this sequence appears to increase expression by 1.5 fold [compare p3300/0 to p-300/0]. Interestingly, none of these promotor CAT constructs are
responsive in VJ-1 CEF. This findings agree with Northern blot data showing
high steady state levels of the apo-Al message in normal CEF, and strongly
suggests that transcriptional mechanisms regulate the apo-Al promotor during
normal and transformed conditions.
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Summary of ApoAl promotor deletion analysis.

Several A poA l reporter CAT constructs containing 5' deletions in the prom otor w ere transfected into VJ-1 and
RCAS CEF.
Sum m ary o f DNA trans-activation studies are shown. Fold over background is calculated as
the per cent acetylation of each construct relative to the negative control: pCA T/Blue. pCA T/Blue is a
prom otor-less reporter CAT construct; positive control: pSV 2CA T/ Blue with SV 40 enhancer and prom otor
sequences.
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Figure 20.

CAT assay of apo-Al promotor CAT constructs.

Responses of apo-A l reporter constructs in VJ-1 and RCAS cells. Lane
designations are: p -6 8 0 0 /0 (l); p-3300/0 (2); p-300/0(3); p-3300/20 (4);
p-300/20 (5); p -193/20 (6); p-3300/43 (7); p-300/43 (8); p -193/0 (9);
negative control used is pCAT/ Blue, a promotor less CAT construct (10);
positive control: pSV2CAT/ Blue containing the SV40 promotor and enhancer
elem ents(ll).
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F igure 21.
Possible m odels fo r eukaryotic gene repression.
Several models for eukaryotic gene repression are illustrated (reference 44). In
model 1, positive transcription is initiated by the formation of a transcriptional
activation complex (TAC) at the transcriptional start site. This complex consists
o f several large heterocomplexes including RNA polymerase II, TATA binding
proteins and co-factors. A positive cw-acting sequence or enhancer region aids in
the formation and stability of the TAC. In general, repression can occur by
disrupting or preventing the formation o f the TAC. In the competition models,
negative factors compete for binding to either the TAC (competition #2), or to
the activator sequence (direct competition #3). In the direct repression model
(#5), a repressor protein binds a functional repressor sequence, or silencer
region, distinct from the activator sequence. Quenching (#4) is accomplished by
protein-protein interactions between the activator and repressor protein; these
larger heterocomplexes recognize adjacent or overlapping ds-acting DNA
sequences to effect repression. This is different from the squelching mechanism
(#6) which does not require DNA binding;
repression occurs when
overexpression of another factor sequesters the functional activator protein, thus,
preventing DNA binding and transcriptional activation. It is important to
remember that these are simplistic models, and that transcriptional repression
could involve multiple combinations of these models depending on the overall
context of the promotor, the availability of transcription factors, and the
physiological cell conditions. Nevertheless, all of these models could potentially
repress a p o -A l in v-Jun transformed CEF.
Legend: A: activator protein; R: repressor protein; B: overexpressed factors;
clear circles: transcriptional activator complex;
arrows indicate the
transcriptional start site; shaded areas represent regulatory elements.
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Putative responsive element identifies a single distinct complex present in
normal nuclear extracts only.
Promotor deletion analysis of the apo-Al regulatory region indicates that
several c/s-acting elements could regulate its expression.

We focused our

attention on the putative responsive element located in the -193 to +20 region.
Studies indicate that this region has a 1.7 fold level of activity over background in
normal CEF,

and is 1.5 fold times higher in normal CEF over VJ-1 cells.

Although this may not be significant, sequence analyses reveals that this region
contains three potential factor binding sites that could regulate apo-Al gene
expression (47) (see figure 15). Since three of the possible repression models
described in figure 21 require DNA binding to effect repression, we wanted to
determine if any repressor heterocomplexes present in normal or transformed
CEF would recognize sites on the -193/20 promotor region.

Gel shift analysis using a labeled 213 bp fragment shows a single distinct
complex present in normal CEF, but absent in v-Jun transformed CEF (fig. 22).
The intensity of the shifted band appears to increases proportionately with
increasing concentration of nuclear extracts. A 100 fold excess of homologous
unlabeled competitor specifically competes with the shifted band, while a non
specific competitor, pGEM 4 plasmid, does not (figure 23). This finding supports
the existence of a specific factor in normal cells that could act as a positive
activator protein. In addition, specific complexes that recognizing the 213 bp
fragment were not detected in v-Jun transformed CEF, suggesting that DNA
binding may not be required to repress the p-193/20 reporter CAT construct in
v-Jun transformed CEF. This observation suggests that a squelching mechanism
may be involved in the repression of the p-193/20 apo-Al -CAT construct.
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DNA binding assay using 213 bp ApoAl promotor fragment

Gel shift analysis using the 213 bp apo-A l promotor fragment encompassing
193 nucleotides upstream from the transcriptional start site and 20 bp o f exon
1 identifies a distinct band present in nuclear extracts from normal CEF (lane
5-7), but barely detectable in v-Jun transformed CEF (lane 2-4). Intensity of
the shifted band appears to increase proportionately with increasing
concentrations of nuclear extracts, lane 1, probe alone;

page 65

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Figure 23.
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Competition shift analysis .

Nuclear extracts from v-Jun transformed CEF (lane 1, 2, A, C) and
normal CEF infected with vector sequences only (lane 3 ,4 , B, D) were
used in a gel shift assay with the 213 bp fragment A 100 fold excess of
unlabeled homologous competitor specifically competes with the labeled
probe in normal extracts (lane 4), while a non-specific sequence does not
(lane D) (at arrows). This suggests the existence of a specific factor in
normal CEF, not found in v-Jun transformed CEF. (lane 5, E: probe
only).
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Antibody shift assays suggest that Jun proteins are absent in heterocomplexes
that recognize the 213 bp fragment

One of the possible models to explain

apo-Al repression in v-Jun

transformed CEF is the squelching model. In this scenario, overexpressed v-Jun
proteins bind to the positive activator proteins and sequester them from binding
to its cognate sequence, hence preventing transcription. To determine if v-Jun
proteins are involved in such a mechanism, Jim antibodies were included in VJ-1
nuclear extracts to possibly neutralize binding to the positive activator protein.
However,

anti-Jun antibodies failed to restore DNA binding to the 213 bp

sequence (lane 3; fig. 24). A possible explanation is that the antibodies were
unable to neutralize overexpressed v-Jun proteins due to large proportional
differences, or that the physical interactions between v-Jun and the activator
protein were stronger.

It would be interesting to see if large amounts of

bacterial expressed v-Jun proteins could squelch DNA binding in normal nuclear
extracts.

Antibody shift assays were also performed to identify other components
of the specific complex in normal nuclear extracts. Other antibodies including
anti-Jun, anti-c-myc, and anti-ras, did not cause a supershift or decrease in band
intensity, indicating that their cognate proteins may be absent from these
complexes (figure 24). More intensive tests are necessary to verify this.
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Antibody gel shift assay

Antibody competition shift assays using several antibodies, including
anti-Jun fail to cause a super-shift or a decrease in band intensity in
normal nuclear extracts (lane 4) suggesting that Jun proteins may be
absent from complexes that recognize the 213 bp fragm ent. lane 1,2: no
antibody; lane 3,4: anti-c-Jun; lane 5,6: anti-c-myc; lane 7,8: anti-ras;
lane 9: probe alone; V J-1: nuclear extracts from v-Jun transformed CEF;
RCAS: nuclear extracts from normal CEF infected with vector sequences
only;
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Chapter IV. DISCUSSION

The

molecular

mechanisms

responsible

for

v-Jun

induced

cell

transformation are not clearly understood (1,2). An interesting possibility is that
v-Jun influences the pattern of target gene expression by inappropriately
activating or repressing its target genes (2). v-Jun behaves this way due to the
structural changes at the protein level that ultimately alter its functional
properties (4). For instance, its stability and dimerization aspects could change.
Consequently, overexpression would increase the repertoire of available Jun
heterocomplexes through an interaction with other nuclear factors. In support
of this, we demonstrate that in vivo Jun complexes exhibit differential binding to
in vitro generated AP-1 target sequences (34).

These observations have

important implications concerning v-Jun induced cell transformation.

In v iv o Jun complexes exhibit differential binding to in vitro generated AP-1

target sequences.
To analyze the DNA binding properties of Jim complexes formed during
overexpression, nuclear extracts from normal, c-Jun overexpressing and v-Jun
transformed CEF were used in a gel shift assay against AP-1 and related AP-1
sequences. Using mutant AP-1 sequences against the consensus AP-1 site in a
competition assay, we were able to demonstrate that Jun complexes formed
during overexpression preferentially recognize distinct subsets of AP-1 related
sequences. This finding suggests that the in vitro substrate specificity may be
altered during Jun overexpression,

relative to the normal condition.

DNA

transactivation studies using these AP-1 related sequences show that their
transcriptional responses were below basal levels in all three nuclear extracts,
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indicating that overexpressed Jun complexes could contribute to transcriptional
repression.

We also investigated the DNA binding properties of Jun complexes
against the consensus AP-1 site. We expected to find more shifted bands, or
more Jun heterocomplexes formed during overexpression,
normal condition.

Instead,

relative to the

our study shows that two distinct Jun

heterocomplexes recognize the consensus AP-1 site in all three cell conditions.
Furthermore, the DNA binding intensities in all three conditions were identical.
This finding is consistent with DNA trans-activation data showing the consensus
AP-1 sequence to be equally responsive in all three cell conditions, with no
significant differences.

Altogether these finding suggest that although Jun

proteins are indeed overexpressed, either very low levels of activated Jun are
required to bind the consensus AP-1 sequence,

or that a majority of Jun

complexes are inactive and do not bind DNA.

Our DNA binding data agrees well with another study investigating the
DNA binding affinities of in vitro translated Jun and Fos family members to
several in vitro generated AP-1 and CREB target sequences. (22). This study
reports that various homodimer and heterodimer combinations of Jun proteins
demonstrate different binding affinities to various AP-1 sequences. For example,
Jun heterodimers bind AP-1 and related sequences with higher affinity, when
compared to Jun homodimers. Moreover, Jim heterodimerization with various
Fos proteins significantly changes the stability and half-life of protein/DNA
complexes, suggesting that Jun dimer partners and their availability influence
binding to AP-1 sites.
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Identification of genes associated with v-Jun induced cell transformation
Having demonstrated that in vivo Jun complexes formed during cell
transformation recognize an altered pattern of in vitro target sequences, we
wished to determine if a similar situation occurs in vivo. We began with the
identification of potential target genes regulated by v-Jun.

Utilizing the

subtractive hybridization and differential display approach, we isolated five
differentially expressed target genes. Clone 4 is a novel cathepsin-like gene that
belongs to a family of related cysteine thiol proteases. This finding is significant
since proteases have long been implicated in cell transformation processes, and
in metastasis of tumor cells.
collagenase,

Furthermore, proteases, such as stromelysin and

are c-Jun target genes. A second gene, the apolipoprotein A -l gene,

is repressed in v-Jun transformed CEF.

Positive regulation of ApoAl expression in normal CEF.
The mechanisms regulating chicken apo-Al expression in normal CEF are
not clearly defined. Differences exist among cell and tissue types, and between
mammalian and avian systems. Promotor deletion analysis in our laboratory
has identified three potential c/s-acting regions on the apo-Al promotor. Two of
these appear to be enhancer regions located at -6.8 kb to -3.3 kb. and -193 to
+ 20 .

We chose to characterize the possible activator sequence located between
-193 to +20 since this region contained several transcription factor binding sites
(47,48,50). O ur DNA binding studies show that this 213 bp fragment recognizes
a single distinct factor present in normal RCAS nuclear extracts, but not in VJ-1
extracts. In addition, antibody shift assays suggest that Jim proteins are absent
from these complexes (figure 24). These findings agree with our Northern blot
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data establishing that the steady state levels of apo-Al mRNA are considerably
higher in normal cells, as compared to v-Jun transformed CEF (figure 7), and
further suggests that positive transcriptional mechanisms regulate apo-Al gene
expression. This finding also agrees with previous studies demonstrating by
DNA trans-activation studies, by DNA binding studies, and by DNA foot
printing analysis that a short segment of the chicken apo-Al promotor
encompassing -60 to -54 nucleotides indeed regulates this gene in several
transformed cell lines (47).

We therefore propose that normal CEF regulate apo-Al expression in a
positive way by at least two activator sequences. One located between -6800 and
-3300 nucleotides,

and another between -193 to +20. Since Actinomycin D

treatments show that mRNA is relatively stable with a half-life of up to 20 hours,
it is possible that the high steady state levels seen in Northern blot analysis is due
to accumulation of stable message expressed from a constitutive promotor.
More likely,

the activator sequence located between -6800 to -3300 would

predominantly regulate this gene.

Negative regulation of ApoAl gene expression in normal CEF.
Several potential mechanisms could repress apo-Al expression in normal
CEF. Promotor deletion analysis suggest that potential repressor sites could be
located between -3.3 kb to -0.3 kb, and on sequences encompassing half of exon
1 (+20 t o +43). For example, expression from the p-3300/0 construct is 1.5 times
weaker than the p-300/ 0 construct. Deletion of the +20 to +43 region appears to
reduce transcriptional responses. For instance, the p-300/43 construct is 4 times
lower than the p-300/20 construct. In addition, a 1.4 fold reduction is observed
between p-3300/20 and p-3300/43. While such discrepancies suggest that more
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defined deletions are necessary to delineate these elements,

it is clear that

negative regulation of apo-Al transcription occurs in normal CEF.

Several

possibilities exist (figure 21). Repression could occur by the direct competition
model (#3), the quenching model (#4), or the direct repression model (#5).
More DNA sequence information,

DNA binding

studies and DNA

transactivation experiments are necessary to determine which of these
mechanisms predominate.

Negative regulation of ApoAl expression in v-Jun transformed CEF.
The apo-Al gene is one of the target genes isolated that appears to be
repressed in v-Jun transformed CEF. Northern blot data show that the steady
state levels of apo-Al mRNA are 3 to 10 times lower in v-Jun transformed CEF,
as compared to normal CEF

(figure 7).

Promotor deletion analysis

demonstrates that all of the reporter CAT constructs containing 5’ deletions are
repressed in v-Jun transformed CEF. Altogether, the observations suggest that
v-Jun overexpression negatively influences apo-Al gene expression.

Possible

repression mechanisms are discussed below.

Repression by DNA binding.
It is conceivable that v-Jun proteins act as repressors and inhibit apo-Al
expression by binding directly on the apo-Al promotor. v-Jun could exert its
repressive action as a heterodimer involving other binding partners. There are
three possibilities:

In the quenching model,

v-Jun heterodimers would

recognize adjacent or overlapping sites on the promotor.
competition model,

In

the direct

v-Jun heterodimers would compete with an activator

protein for a common regulatory site. In the direct repression model, v-Jun
heterodimers w ould bind to a silencer region on the promotor. Alternatively, vpage 73
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Jun might not bind the apo-Al promotor, but indirectly influence apo-Al by
inducing the expression of a functional repressor protein.

Further proof of

which models are responsible depends on demonstrable DNA binding of v-Jun
complexes to distinct promotor regions, and identification of repressor regions
on the ApoAl promotor by DNA transactivation studies.

Repression not involving DNA binding.
In an attempt to demonstrate that v-Jun overexpression influences apo-Al
expression, we investigated the regulation of the p-193/20 reporter construct in
a DNA transactivation study. We chose this region since it contains several
transcription factor binding sites.

Our preliminary analysis suggest that

expression of this construct is 1.7 times lower in v-Jun transformed CEF, as
compared to normal CEF. Although this may not be significant, DNA binding
studies suggest that no apparent "repressor protein" recognizes this region,
suggesting that DNA binding may not be required for repression of this
sequence. Interestingly, these observations agree well with a squelching model
of repression.

As mentioned earlier,

this model depends on the active

sequestering of potential regulators that effect repression by preventing DNA
binding, and eliminating positive transactivation of its target genes. More work
is necessary to verify this.

Implications of study on v-Jun induced cell transformation.
The results of this study have important implications concerning the
mechanisms involved in v-Jun induced cell transformation. Overexpression of vJun proteins can result in two related possibilities that ultimately lead to cell
transformation: an increase in the repertoire of potential transcription factors,
and squelching of target genes. Each possibility will be discussed below.
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One possibility is that the repertoire of possible transcription factors is
increased.

This can occur since Jun proteins can interact with a variety of

transcription factors,

both at the DNA level and through protein-protein

interactions (10-15, 18-21, 23, 51). The increased repertoire can consist of both
activator and repressor complexes which could influence gene expression by
either transcriptional activation or repression.

The new repertoire would

recognize variations in AP-1 sequences, or bind to new non-AP-1 sites. Since
this illicit event is not stringently controlled, cell transformation can develop.
These assumptions are supported by the observations in the study. For instance,
overexpression of v-Jun proteins leads to a change in substrate specificity in vitro,
suggesting a change in the pattern of target gene expression in vivo. Indeed,
our study has identified two genes showing altered patterns of gene expression,
although the role of these genes in cell transformation has yet to be established.

The second possibility of v-Jun overexpression is a squelching phenomena
(54, 55). In this situation, v-Jun actively sequesters other transcription factors
rendering them as inactive complexes.

As a result,

target genes of the

sequestered factor are repressed. If such genes are important in the regulation
of cell proliferation, cell transformation could occur. Evidence suggests that
overexpressed c-Jun proteins could indeed interact with members of the steroid
receptor family of transcription factors, and squelch their target genes (11, 12).
Again, these assumptions reflect the observations of the study. For example,
no change in DNA binding or DNA transactivation occurs using the consensus
AP-1 sequence. DNA transactivation using mutant AP-1 sequences produced
responses that were below basal levels,

suggesting that a majority of the

overexpressed Jun complexes may be inactive. Indeed,

the v-Jun induced
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repression of ApoAl during cell transformation may occur by a squelching
mechanism.

Intuitively,

neither possibility would predominate to effect cell

transformation. Rather, a combination events would occur; the outcome would
ultimately depend on promotor structure, or the organization of enhancer and
repressor sites along the upstream regulatory region. Studies show that c-Jun
proteins can interact with other nuclear factors resulting in DNA binding to new
non-AP-1 sites. These members include the steroid hormone receptor family,
myoD, and NF-KB (10-15, 18-21, 23, 51). Studies suggest that the promiscuous
behavior of c-Jun proteins may contribute to changes in the pattern of target
gene expression, and could ultimately be responsible for a variety of cellular
responses.

It is therefore possible that overexpressed v-Jun could behave

similarly. If this is so, these newly formed Jun-heterocomplexes with longer
half-lives could interact with both activator and repressor factors serving to
either positively or negatively affect their target genes. This could drastically
alter the pattern of target gene expression. In support of this, the dissertation
project has identified two target genes showing altered patterns of gene
expression: clone 4, which probably functions as a protease, is overexpressed in
v-Jun transformed CEF,

while apo-Al,

responsible for overall cholesterol

metabolism, is repressed. Indeed, more deregulated genes are anticipated.
Potential candidates include genes coding for positive and negative regulators
and effectors whose aberrant expression would change the balance in favor of
cell transformation. Potential repressed targets include tumor suppressor genes,
negative cell cycle regulatory genes, or anti-apoptosis genes; activated targets
would include oncogenes, positive cell cycle regulators, growth factors and their
receptors, or positive signal transducers.
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Undoubtedly,

interactions occurring from overexpression are not the

only explanation for v-Jun induced cell transformation. Clearly, more than one
mechanism could be responsible since cell transformation is a complex process
requiring multiple independent but related steps.

For example,

v-Jun

homodimers alone are sufficient to transform CEF (33). A major c-Jun partner,
c-Fos, is not required. Overexpression of a chimeric v-Jun construct (VJ-GLZ)
that only forms homodimers through the GCN4 leucine zipper,
transforms CEF.

Interestingly,

weakly

the phenotypic characteristics of VJ-GLZ

transformed CEF differ from v-Jun transformed CEF: the former are arranged
in random focal arrays as compared to

circular swirls observed in v-Jun

transformed CEF. Their kinetic properties are different too; the transformation
potential of VJ-GLZ homodimers resembles c-Jun: weak and inefficient. Rapid
transformation obviously requires other parameters, perhaps partners that do
not involve dimerization.

Although this last study suggests that v-Jun induced cell transformation in
CEF does not require dimerization with c-Fos or other nuclear factors, and may
accomplish this without increasing the repertoire of Jun heterocomplexes, it
does not argue against it. It is possible that potential interactions occur with
other nuclear factors that do not involve the Jun leucine zipper.
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CHAPTER V.

FUTURE DIRECTIONS

The dissertation project tests the hypothesis that deregulated expression
of v-Jun contributes to cell transformation in CEF by influencing the pattern of
target gene expression. It predicts that several downstream target genes would
be activated or repressed inappropriately. In support of this, two target genes
were isolated showing altered patterns of gene expression For this reason,
identification of other target genes is necessary, if not mandatory.

Importance of clone 4.
An important concern is the transcriptional regulation of clone 4 during
normal and transformed conditions. Although a differential pattern of clone 4
gene expression has been demonstrated, it is not certain if it is a direct or indirect
primary gene target of v-Jun, or a secondary target expressed as a consequence
of cell transformation. Likewise, if done 4 is a primary target, can basal levels
of c-Jun regulate this protease during normal conditions?
question,

To address this

investigations on its regulation at the transcriptional level are

necessary, as well as the identification of AP-1, or essential non-AP-1 binding
sites on the promotor.

Furthermore,

the regulatory factors governing its

functional aspects at the protein level should not be ignored. Answers to these
questions relate to its possible involvement in cell transformation, as will be
discussed below.

Several approaches to correlate a role for clone 4 in cell transformation
exist. One strategy is to determine the functional aspects of clone 4 during
normal conditions,

and investigate how its deregulated overexpression may

contribute to cell transformation. Since extensive nudeotide and amino add
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sequence analysis indicates that this gene could belong to a family of related
cathepsin-like proteases, several important questions arise, including: what is
its chromosomal location, and is this a site of known chromosomal aberration?,
What is its tissue distribution? Where is its predominant cellular location, or
sites of action?

Since most proteases are initially produced in an inactive

proenzyme form, what are the requirements for optimal activity? What are its
direct substrates?

Important answers to the functional aspects clone 4 will

provide us with clues on how its deregulation may contribute to cell
transformation in CEF. For instance, well known proteases like stromelysin and
cathepsin, have been implicated in tumor progression and metastasis (104, 105).
Interestingly,

stromelysin is a Jim target gene.

Its direct substrates are

extracellular matrix components. It would be interesting to see if clone 4 belongs
to the cathepsin family of proteases possessing similar functional properties,
since cathepsins are a prognostic tumor marker for breast cancer (105).

Another strategy to establish a role for clone 4 in transformation is to
determine its requirements in v-Jun induced transformation. For instance, will
overexpression of clone 4 be sufficient to transform CEF? Rapid transformation
occurring independent of v-Jun activation suggests a strong correlation, while
weak to no transformation will indicate that clone 4 may be required, but not
sufficient. In a similar way, if done 4 is a downstream effector of v-Jun, then
blocking clone 4 expression, or activity during v-Jun overexpression, should
reduce v-Jun's transformation potential.

Possible sites of inhibition could be

accomplished at the transcriptional or translational level (with antisense RNA),
or at protein level (with done 4 antibodies). Answers to these questions would
also confirm if clone 4 is a primary or secondary target of v-Jun.
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Importance of Apo lipoprotein A1
The transcriptional control mechanisms regulating apo-Al expression
during normal and transformed conditions have not yet been resolved
completely.

In addition to the mechanisms proposed earlier,

two studies

suggest that other factors may be involved. First, studies show that the steroid
family of transcription factors cooperate best with Jun proteins to regulate gene
expression. Quite remarkably, the apo-Al promotor contains several potential
steroid binding sites located between -193 to +20 (see figure 15). It would be
interesting to see whether these factors act exclusively, or in concert with Jun
proteins to regulate Apo-Al gene expression.

Second,

it is possible that cholesterol could directly affect apo-Al

transcription. Recently, low levels of membrane cholesterol have been shown
to regulate transcription by stimulating the cleavage and post-translational
activation of an ER- membrane bound transcription factor,

SREBP-1 (sterol

regulatory element binding protein -1) (reviewed in reference 106). Intriguingly,
SREBP-1 and -2 belongs to a family of bHLH-ZIP (basic-helix-loop-helix leucine
zipper) transcription factors responsible for the regulation of low density
lipoprotein (LDL) receptor through the SRE (sterol regulatory element). These
observations raise several possibilities on the role of Jun proteins and apo-Al
regulation.

Since Apolipoprotein-Al is a constituent of HDL (high density

lipoproteins) involved in regulating cholesterol mobilization, it is conceivable
that concentrations of cholesterol could in turn regulate apo-Al expression
through SREBP-1. Although the SREBP leucine zipper does not resemble the Jun
leucine zipper,

it is conceivable that

overexpression of v-Jun would form

SREBP/ Jun heterocomplexes to repress apo-Al transcription by a squelching
mechanism. It would be interesting to see if a SRE site exists on the apo-Al
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promotor. This would suggest that cholesterol or SREBP may regulate apo-Al
similar to the LDL receptor during normal conditions, and that this site may be
squelched during v-Jun overexpression. Answers to these questions can provide
clues on how deregulated expression may contribute to cell transformation.

Another interesting inquiry is a possible role for apolipoproteins in cell
transformation, in vitro, or tumorigenesis in vivo. An indication that this may be
so comes from studies with ApoE demonstrating its ability to regulate neuronal
grow th in vitro (107). This study shows that ApoE3 increases neurite outgrowth
in neurons in vitro, while an ApoE isoform ApoE4, has the opposite effect.
These ApoE mediated cellular responses are believed to occur through low
density lipoprotein (LDL) receptor interactions,

since blocking with specific

antibodies, affects ApoE mediated response. However, it is not certain if these
growth related events are mediated by extracellular receptor signaling
pathways, or from internalized ApoE /LDL receptor complexes, and whether
the responses are specific to neural cells only. Nevertheless, other studies show
that HDL (high density lipoprotein) and LDL mediated receptor binding
stimulates signaling events involving phosphoinositide catabolism and Ca+2
mobilization in a number of cell types, including smooth muscle cells (111). In
kidney mesangial cells, LDL receptor activation induces a number of growth
related genes, including c-Fos and c-Jun transcription (109). Since Apo-A and
Apo-E share similar regulatory roles,

namely the mobilization of plasma

cholesterol, it is conceivable that HDL containing Apo-Al lipoproteins would
behave in a similar manner to affect cellular growth responses,
deregulated overexpression would cause transformation.

such that

Future studies to

establish such a role should therefore include a possible autocrine pathway
where secreted ApoAl would influence cellular growth responses,

perhaps
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through the HDL recrptor.
Finally, understanding the transcriptional mechanism regulating done 4
and apo-Al, as well as their requirements in cell transformation, would give us
an idea on how future Jun target genes might be regulated. One could expect
the isolation of other deregulated Jun targets,

the identification of new

transcription factors interacting with Jim, how these factors cooperate to affect
transcription,

and why activation should occur instead of repression.

This

information would help us undertake strategies to correct for Jun related
disorders, which can be investigated by gene therapy.
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